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1	  Zusammenfassung 
Ziel dieser Doktorarbeit war es, die Funktion von SIRT1 und Peroxisome proliferator-
activated receptor γ (PPARγ) coactivator 1α (PGC-1α) in der Atherosklerose zu erforschen. 
Atherosklerose ist eine chronisch inflammatorische Erkrankung die aus einem komplexen 
Zusammenspiel der Gefässwand mit Makrophagen, T Zellen und oxidierten LDL 
(Lipoprotein niederer Dichte) entsteht. Die Ruptur eines atherosklerotischen Plaques kann zur 
Bildung eines Thrombus führen und das Gefäss ganz verschliessen, was im schlimmsten Fall 
zu einem Herzinfarkt oder Schlaganfall führen kann. SIRT1 und PGC-1α sind Enzyme die 
wichtige metabolische und anti-inflammatorische Eigenschaften besitzen. SIRT1 ist ein 
Sirtuin (Klasse III Histone-Deacetylase), welches in der Lebensverlängerung durch eine 
niedrige Kaloriendiät sowie in metabolischen Schaltkreisen in verschiedenen Organismen 
beteiligt ist. PGC-1α ist ein transkriptioneller Kofaktor der die mitochondriale Biogenese und 
ebenfalls metabolische Prozesse reguliert. Die Deacetylierung von PGC-1α durch SIRT1 führt 
zur Aktivierung dieses nicht DNA-bindenden Kofaktors. 
Um die Rolle dieser Moleküle in der Atherosklerose zu untersuchen, haben wir SIRT1+/- oder 
PGC-1α-/- mit atherosklerotischen ApoE-/- Mäusen gekreuzt, um dann ApoE-/- SIRT1+/+ mit 
ApoE-/- SIRT1+/- bzw. ApoE-/- PGC-1α+/+ mit ApoE-/- PGC-1α-/- Mäusen zu vergleichen. 
Wir haben herausgefunden, dass haploinsuffiziente ApoE-/- SIRT1+/- Mäuse mehr 
Atherosklerose als die ApoE-/- SIRT1+/+ Mäuse haben. Desweiteren konnten wir zeigen, dass 
die Supprimierung des NF-κB Signalwegs durch SIRT1 die Endothelzellaktivierung reduziert, 
die Lox-1 Expression und Schaumzellbildung der Makrophagen inhibiert, sowie die 
endotheliale Expression von Thromboplastin (Faktor III, tissue factor) supprimiert. 
ApoE-/- PGC-1α+/+ und ApoE-/- PGC-1α-/- Mäuse bilden in etwa gleich viel Atherosklerose. 
Allerdings sind die ApoE-/- PGC-1α-/- Mäuse leichter und haben einen deutlich geringeren 
epididymalen Fettanteil, weniger Triglyceride im Plasma und eine differentielle Expression 
von wichtigen pro- und anti-inflammatorischen Molekülen. Eine Balance dieser Effekte 
könnte dazu führen, dass wir keinen atherosklerotischen Unterschied in diesen Mäusen 
beobachten können.  
Während PGC-1α sowohl pro- als auch anti-atherosklerotische Eigenschaften besitzt, zeigen 
unsere Ergebnisse, dass SIRT1 vor allem protektive anti-atherosklerotische sowie anti-
thrombotische Eigenschaften aufweist. Daher stellt SIRT1 ein vielversprechendes Zielgen für 
pharmakologische Therapieansätze für Patienten mit kardiovaskulären Erkrankungen dar. 
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2	  Summary	  
The aim of this PhD thesis was to investigate of the role of SIRT1 and Peroxisome 
proliferator-activated receptor γ (PPARγ) coactivator 1α (PGC-1α) in atherosclerosis. 
Atherosclerosis is a chronic inflammatory disease resulting from the interaction of the vessel 
wall with macrophages, T cells and oxidized low-density lipoproteins (oxLDL). Rupture of an 
atherosclerotic plaque may result in thrombus formation and complete vessel occlusion, the 
primary cause of myocardial infarction and stroke. SIRT1 and PGC-1α are enzymes with 
important functions in various metabolic and anti-inflammatory processes. SIRT1 is a class III 
histone deacetylase that mediates the effects of caloric restriction on lifespan and metabolic 
pathways in various organisms. PGC-1α is a transcription coactivator involved in 
mitochondrial biogenesis and metabolic processes; it is a target protein of SIRT1.  
To study the role of these molecules in atherosclerosis, we crossed SIRT1+/- or PGC-1α-/- with 
atherosclerosis-prone ApoE-/- mice, and compared ApoE-/- SIRT1+/+ with ApoE-/- SIRT1+/- mice 
as well as ApoE-/- PGC-1α+/+ with ApoE-/- PGC-1α-/- mice, respectively. 
We found that haploinsufficient ApoE-/- SIRT1+/- mice developed more atherosclerotic lesions 
than ApoE-/- SIRT1+/+ mice. Using in vitro, ex vivo and in vivo approaches, we showed that 
the atheroprotective effects of SIRT1 are mediated via suppression of NF-κB signaling: 
SIRT1 prevents the expression of endothelial adhesion molecules and reduces the expression 
of the scavenger receptor Lox-1 as well as macrophage foam cell formation. We further 
demonstrated that suppression of NF-κB signaling diminishes the expression of tissue factor 
(coagulation factor III) in human aortic endothelial cells.  
ApoE-/- PGC-1α+/+ and ApoE-/- PGC-1α-/- mice did not differ in the amount of their 
atherosclerotic lesions. ApoE-/- PGC-1α-/- mice had markedly reduced body and epididymal 
white adipose tissue (WAT) weight, less plasma triglycerides, and differential expression of 
various pro and anti-atherogenic factors. A balance of these anti- and pro-atherogenic factors 
may explain the unchanged atherosclerotic phenotype of ApoE-/- PGC-1α-/- mice. 
Taken together, our data reveal that the role of PGC-1α in atherogenesis remains to be 
clarified. On the other hand, SIRT1 has both anti-atherogenic and anti-thrombotic functions. 
Our findings suggest that SIRT1 activation may be a promising therapeutic approach to 
impede atherosclerosis. 
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  Abbreviations	  
12/15-LO 12/15-Lipooxygenase 
ACAT Acyl CoA:cholesterol acyltransferase 
acLDL Acetylated LDL 
ADP Adenosine diphosphate 
AMP Adenosine monophosphate 
ApoE Apolipoprotein E 
ATP Adenosine triphosphate 
ATVD Atherothrombotic vascular disease 
BM Bone marrow 
BMT Bone marrow transplantation 
BrdU Bromodeoxyuridine 
CVD Cardiovascular disease 
DAPI 4’-6-Diamidino-2-phenylindole 
DiI 1,1’,di-octadecyl-3,3,3’3’-tetramethylindocarbocyanine perchlorate 
DiO 3,3’-dioladecyloxacarbocyanine perchlorate 
DOI Digital object identifier 
E-Sel E-Selectin 
EC Endothelial cell 
eNOS Endothelial nitric oxide synthase 
FOXO Forkhead box O (e.g., FOXO1, FOXO3, FOXO4) 
GR Glucagon receptor (also called Gcgr) 
HAEC Human aortic endothelial cell 
HAT Histone acetyltransferase 
HDL High density lipoprotein 
HSL Hormone sensitive lipase 
ICAM-1 Intercellular adhesion molecule 1 
IDL Intermediate density lipoprotein 
iNOS Inducible nitric oxide synthase 
LDL Low density lipoprotein 
LDL-R LDL-Receptor 
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Lox-1 Lectin-like oxidized LDL receptor 1 (also called Olr1) 
LPS Lipopolysaccharide 
LXRα/β Liver x receptor 
MCP-1 Monocyte chemoattractant protein 1 (also called chemokine (C-C motif) 
ligand 2 or Ccl2) 
MPO Myeloperoxidase 
NAD Nicotinamide adenine dinucleotide 
NAM Nicotinamide 
NF-κB Nuclear factor kappa B 
NO Nitric oxide 
OAADPr O-acetyl-ADP-ribose 
ORO Oil red O 
oxLDL Oxidized LDL 
PC Phosphatidyl choline 
PGC-1α PPARγ coactivator 1α 
PLA2 Phospholipase A2 
PLC Phospholipase C 
PPAR Peroxisome proliferator-activated receptor (e.g., PPARα, PPARβ/δ, PPARγ) 
PMID PubMed unique identifier 
ROS Reactive oxygen species 
siRNA Small interfering RNA 
SIRT1 Sirtuin 1 (silent mating type information regulation 2, homolog) 1 
SMase Sphingomyelinase 
SR-A Scavenger receptor A 
SR-B Scavenger receptor B 
SR-PSOX/ 
CXCL16 
Scavenger receptor for phosphatidylserine and oxidized lipoprotein/CXC 
chemokine ligand 16 
TF Tissue factor (also called coagulation factor III or Fe) 
TNF-α Tumor necrosis factor alpha 
VCAM-1 Vascular cell adhesion molecule 1 
VSMC Vascular smooth muscle cell 
vWF Von Willebrand factor 
WAT White adipose tissue 
WT Wild-type 
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4	  Introduction	  
4.1 Atherosclerosis 
The exact date of the first description of the process of atherosclerosis is unknown. Early in 
the 20th century, Nikolai Anitschkow demonstrated that a cholesterol-rich diet leads to the 
accumulation of cholesterol in the arterial wall of rabbits, and consequently to the 
development of atherosclerotic plaques (Anitschkow and Chalatow, 1912). This was the first 
link between cholesterol feeding and atherosclerosis. Today it is well recognized that 
cholesterol promotes atherosclerosis and cardiovascular diseases (CVD) (Steinberg, 1989). 
Atherosclerosis is the major cause of myocardial infarction and stroke, the two leading causes 
of mortality in the Western world (Hansson, 2005). Atherogenesis, the developmental process 
of atheromatous plaque formation, is a chronic inflammatory disease that results from 
interaction between modified low-density lipoproteins (LDL), activated endothelial cells 
(EC), monocyte-derived macrophages, T cells, and the vessel wall (Hansson, 2005) (Figure 
1). The main steps in atherogenesis will be explained in more detail, focusing on the 
molecular aspects of the disease. 
 
Figure 1 Model of atherogenesis 
(see next page) Upon activation, endothelial cells (EC) express adhesion molecules (e.g., 
ICAM-1, blue, and VCAM-1, red) upon activation. Blood monocytes bind to these adhesion 
molecules, transmigrate from the arterial lumen (blood) into the arterial intima, and 
differentiate into macrophages. Increased uptake of modified LDL (mainly oxLDL) via 
scavenger receptors or decreased cholesterol efflux accelerates the accumulation of 
intracellular free cholesterol and cholesteryl ester-loaded lipid droplets that promote foam 
cell formation. Macrophages also interact and present antigens to T helper cells (Th cell). 
Macrophage foam cells eventually die and fall apart, thereby forming a necrotic core. 
Advanced, vulnerable plaques can rupture and contribute to the formation of an arterial 
thrombus, which may lead to myocardial infarction or stroke. 
 
- 11 -
 
 
 
 
- 12 -
 
 
Atherogenesis starts during embryonic development 
Atherosclerosis it is a long-term disease that starts early in human development. Studies on 
premature human fetuses revealed that the formation of fatty streaks, small sub-endothelial 
deposits of monocyte-derived macrophages, may already start during embryonic development 
(Napoli et al., 1997). Although the placenta is impermeable to native LDL particles and 
children of hypercholesterolemic mothers generally have normal cholesterol levels, a 
correlation between maternal and fetal plasma cholesterol suggests that during early stages of 
pregnancy, maternal hypercholesterolemia may promote lesion formation in the fetus (Napoli 
et al., 1997; Palinski and Napoli, 2002).  
LDL modifications – a key trigger of atherosclerosis 
Lipoproteins are the cholesterol carriers in the blood stream. An LDL particle is mainly 
composed of ~ 700 phospholipids, ~ 600 free cholesterols, ~ 1600 cholesteryl esters, ~ 185 
triglycerides, and one large apoB-100 protein (Esterbauer et al., 1992). LDL particles become 
atherogenic especially after undergoing covalent modifications that affect their functionality 
and receptor-binding specificity. These modifications are introduced by different proteolytic 
and lipolytic enzymes and oxidants. Chymase, tryptase, plasmin, kallikrein, thrombin and 
other types of proteases and matrix metalloproteinases are capable of cleaving apoB-100. 
Lypases, such as phospholipase A2 (PLA2), phospholipase C (PLC), sphingomyelinase  
(SMase), or carboxyl ester lipase, catalyze the hydrolysis of fatty acid esters, phospholipids, 
sphingomyelins, and lysophospholipids, respectively. Enzymes that oxidize LDL include 
12/15-lipooxygenase (12/15-LO), myeloperoxidase (MPO), and heme-oxygensase I (Oorni et al., 
2000). Protein modifications can generate neoepitopes (e.g. ‘oxidation-specific’ epitopes) that 
are recognized by ‘ox-LDL’ antibodies in vitro and by macrophage scavenger receptors in 
vivo (Horkko et al., 1996; Palinski et al., 1996). 
The most studied LDL modification is oxidation. LDL can be oxidized nonenzymatically and 
enzymatically. Nonenzymatic oxidations can be performed in vitro using copper ions (Cu2+), 
which oxidize a large amount of polyunsaturated fatty acids (PUFA), increase the hydrate 
density of the particle and drastically alter the apoB-100 protein. These oxidative changes can 
be blocked with antioxidants, such as vitamin E (α-tocopherol) or probucol (Esterbauer et al., 
1992; Henriksen et al., 1981; Olsson and Yuan, 1996; Steinbrecher et al., 1984). Enzymatic 
modifications of LDL can be achieved by incubating LDL with endothelial cells (EC), 
vascular smooth muscle cells (VSMC), monocytes, macrophages, fibroblasts or neutrophils. 
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The enzymatic function comes from 12/15-LO, inducible nitric oxide synthase (iNOS), MPO, 
NAPDH oxidase, and other peroxidases (Steinberg, 2009). 
Endothelial dysfunction – an early manifestation of atherosclerosis 
Under physiological conditions the neurotransmitter acetylcholine binds to specific G protein 
coupled receptors on endothelial cells and the downstream signaling pathway leads to 
phosphorylation and activation of the endothelial nitric oxide synthase (eNOS). eNOS uses L-
arginine as substrate to generate citrulline and nitric oxide (NO). NO diffuses to adjacent 
vascular smooth muscle cells (VSMCs) and activates an enzymatic pathway that leads to the 
relaxation of smooth muscle cells and, consequently, to vessel dilation (Murad, 2006). NO 
exerts additional protective effects such as prevention of monocyte adhesion to the endothelial 
layer, reduction of smooth muscle cell proliferation, and inhibition of platelet activation and 
aggregation (Forstermann, 2010). 
Loss of proper endothelial function leads to chronic endothelial dysfunction, which is an 
indicator of CVD and an early step in atherogenesis (Kawashima and Yokoyama, 2004). 
Excessive production of reactive oxygen species (ROS) and oxidant stress, which are often 
observed in patients with hypertension, hypercholesterolemia or diabetes, impairs NO 
production and chemically inactivates NO to form toxic peroxynitrite (ONOO−) 
(Forstermann, 2010). Peroxynitrite may ‘uncouple’ eNOS, which means that the oxygen 
reduction is uncoupled from the NO synthesis, thereby yielding a dysfunctional superoxide-
generating enzyme that enhances vascular oxidative stress (Laursen et al., 2001). These and 
several other consequences of impaired NO synthesis affect endothelial function and induce a 
sustained endothelial inflammatory activation that contributes to the development of 
atherosclerosis (Deanfield et al., 2007; Kawashima and Yokoyama, 2004; Mueller et al., 
2005; Stokes et al., 2001). 
Endothelial activation and inflammatory cell recruitment 
Cytokines (e.g. interleukins and TNF-α) and constituents of modified lipoproteins (e.g. 
lysophosphatidyl choline) lead to increased oxidative stress in endothelial cells, which in turn 
activates the NF-κB signaling pathway. Activated NF-κB migrates into the nucleus and 
induces the expression of numerous genes, including many pro-inflammatory genes such as P-
Selectin, ICAM-1, and VCAM-1 (Collins et al., 1995; Gareus et al., 2008). These endothelial 
cells are considered ‘activated’. In contrast, under physiological conditions aortic endothelial 
cells do not express these adhesion molecules, except for low constitutive levels of ICAM-1 
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(Wood et al., 1993). Secretion and presentation of these molecules attract and activate blood 
monocytes, which then transmigrate into the arterial intima. This transmigration of monocytes 
is stimulated by chemokines, such as monocyte chemoattractant protein-1 (MCP-1), MCP-4, 
regulated on activation normal T cell expressed and secreted (RANTES), and IL-8, which 
bind to G protein coupled-receptors and are expressed by various vascular cells (Zernecke et 
al., 2008). Adhesion of mononuclear phagocytes to activated endothelial cells starts early in 
atherogenesis (Faggiotto et al., 1984; Poole and Florey, 1958), suggesting that endothelial 
activation is an early inflammatory step of the disease. 
Cholesterol uptake and macrophage foam cell formation  
Infiltration of monocyte-derived macrophages into the subendothelial space is a key step in 
atherogenesis. These invading macrophages release and respond to inflammatory mediators 
and interact with cytotoxic (Tcyt) and helper (Th) T cells. While in vitro incubation of 
monocytes or macrophages with native LDL does not lead to cholesterol accumulation, 
incubation with acetylated LDL (acLDL) leads to a quick accumulation of cholesterol and 
foam cell formation (Goldstein et al., 1979). The reason is that the LDL receptor is 
downregulated when cholesterol concentrations increase in the cell (receptor-down 
regulation), whereas the receptor that recognizes acLDL, scavenger receptor A (SR-A), is not 
downregulated. The same concept holds true for other scavenger receptors. Instead of being 
downregulated at increasing intracellular cholesterol concentrations, some of them are even 
upregulated, thereby providing a fast and uni-directional accumulation of cholesterol from 
modified lipoproteins, such as acLDL and oxLDL (Steinberg, 2002).  
Table 1 Classes of scavenger receptors 
Class Scavenger receptor 
A SR-AI, SR-AII, SR-AIII, MARCO, SRCL 
B SR-BI, CD36 
E Lox-1 
F SREC-I, SREC-II 
G SR-PSOX/CXCL16 
 
Macrophage scavenger receptors (SRs) are classified into SR families based on their 
structural similarity (Table 1). The most prominent SRs that are expressed in atherosclerotic 
lesions include the scavenger receptor types AI and AII (Kodama et al., 1990; Rohrer et al., 
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1990), CD36 (Endemann et al., 1993), lectin-like oxidized LDL receptor-1 (Lox-1) 
(Sawamura et al., 1997) and scavenger receptor for phosphatidylserine and oxidized 
lipoprotein/CXC chemokine ligand 16 [(SR-PSOX)/CXCL16] (Matloubian et al., 2000; 
Shimaoka et al., 2000).  
Modified LDL particles are bound and ingested by scavenger receptors, and then delivered to 
lysosomes, where cholesteryl esters are enzymatically hydrolyzed to free cholesterol and fatty 
acids (Figure 2). Acyl CoA:cholesterol acyltransferase (ACAT; also called sterol O-
acyltransferase or SOAT) catalyzes the formation of cholesteryl ester from free cholesterol, 
which accumulates in lipid droplets that lead to the foamy appearance of the cells. The 
hormone sensitive lipase (HSL; also known as neutral cholesterol hydrolase or NCEH) is a 
neutral lipase that reverses this esterification by mediating cholesterol ester hydrolysis, 
yielding free cholesterol (Li and Glass, 2002) (Figure 3).  
 
Figure 2 Cholesterol influx and efflux 
Uncontrolled binding and uptake of modified LDL particles into macrophages is mediated 
by scavenger receptors, such as SR-A, Lox-1, and CD36. The lipoprotein particles are 
digested in lysosomes, and the resulting free cholesterol particles are released into the 
cytoplasm. Excess free cholesterol in the cytoplasm is esterified by ACAT to cholesteryl 
esters, which then accumulate in lipid droplets. HSL hydrolyzes cholesteryl esters back to 
free cholesterol. Additionally, free cholesterol can be used for reverse cholesterol transport, 
a process that is supported by ABC transporters, such as ABCA1 and ABCG1, and the 
scavenger receptor SR-BI. 
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The physiological role of scavenger receptors is the recognition and clearance of pathogens 
and apoptotic cells. However, many scavenger receptors have pleiotropic functions. For 
example, CD36 is involved in uptake and internalization of oxidized phospholipids and 
lipoproteins as well as apoptotic cells and pathogens in phagocytes, it binds to and supports 
the transport of long-chain fatty acids in adipose tissue and muscle, and in sensory cells it is 
involved in pheromone signaling in insect and fatty food preference in rodents (Silverstein 
and Febbraio, 2009). 
An important and unresolved question is: Why do these receptors take up cholesterol in an 
uncontrolled manner? A perspicuous answer may be that modifications in lipoprotein contents 
resemble pathogen-associated molecular patterns (PAMPs) that are normally recognized by 
these pathogen recognition receptors (PRRs) in innate immunity. For example, phosphatidyl 
choline (PC) moieties of oxLDL mimic the PCs found on the surface of many pathogens, and 
one PPR for this molecular pattern is the scavenger receptor CD36 (Horkko et al., 1999; 
Horkko et al., 1996).  
 
Figure 3 Macrophage foam cell 
Treatment of macrophages with oxLDL leads to 
intracellular cholesterol accumulation and gives the 
cells their foamy appearance. (A) Brightfield image 
of peritoneal macrophages that were treated with 
oxLDL and stained with Oil Red O (ORO). The 
lysochrome diazo dye ORO stains neutral 
triglycerides, lipids, and lipoproteins. Lipid droplets 
are stained red. (B) Phase contrast image of RAW 
264.7 macrophages upon treatment with DiI-labeled 
oxLDL. DiI is a carbocyanine, fluorescent lipophilic 
dye, with its emission in the yellow/red spectrum. 
Magnifications, x400. Nuclei are stained with DAPI, 
light blue to violet. 
 
Reverse cholesterol transport 
Mammalian cells are unable to degrade the sterol ring of cholesterol, and most excess sterols 
can only be eliminated from the body by biliary excretion. Therefore, macrophages and other 
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cell types must export cholesterol to extracellular acceptors, mainly HDLs, for transport to the 
liver. This reverse cholesterol transport involves many enzymes and receptors, such as liver X 
receptors (LXRs) and their binding partners retinoid X receptor (RXRs), peroxisome-
proliferator activated receptors (PPARs), the ABC transporters ABCA1 and ABCG1 as well 
as the scavenger receptor SR-BI. An dysfunctional reverse cholesterol transport may lead to 
excessive accumulation of cholesterol in the cell and therefore stimulate foam cell formation 
and disease progression (Li and Glass, 2002). 
Adaptive immunity in atherosclerosis 
The adaptive immunity is composed of the lymphatic B and T cells. While B cells are only 
marginally detectable in atherosclerotic plaques, T cells are quite abundant (up to 20% of 
plaque cells) and play an important role in atheromatous plaque formation. T cells can be 
subdivided into cytotoxic (CD8+ T cells, Tcyt) and helper T cells (CD4+ T cells, Th), and the 
helper T cells can be further subclassified as Th1, Th2, Treg (regulatory T cells), and Th17 
cells, depending on the cytokines that these cells secrete after activation.  
LDL-R-/- RAG1-/- or ApoE-/- DNA-PK-/- mice have no lymphocytes and develop less 
atherosclerosis than immunocompetent control mice (Song et al., 2001; Zhou et al., 2000). 
Th1-slanted ApoE-/- C57BL/6 mice develop more atherosclerosis compared with ApoE-/- 
BALB/c mice, which display predominantly Th2 responses by CD4+ T cells, supporting a 
proatherogenic role for Th1 response (Schulte et al., 2008). In addition, atherosclerotic 
plaques generally display high IFN-γ (Th1 marker) and low IL-4 (Th2 marker) levels, 
suggesting that Th1 cells are the primary T cell subtype found in plaques. Furthermore, 
expression of the CD45 RO isoform and secretion of IFN-γ suggest that most plaque T cells 
are activated (Packard et al., 2009). Tregs play a crucial role in the maintenance of tolerance 
to self-antigens and the regulation of adaptive immunity. Tregs have an anti-atherogenic 
function by suppressing the activation of other T cells in secondary lymphoid organs or 
directly in the plaques (Packard et al., 2009). 
The role of B cells in atherosclerosis is less clear. While some groups reported that B cells 
have an overall protective function in atherosclerosis (Caligiuri et al., 2002; Major et al., 
2002), a recent study demonstrates that depletion of mature B cells using CD20 antibodies 
decreases atherosclerosis (Ait-Oufella et al., 2010). 
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Plaque vulnerability 
Human atherosclerotic plaques can be divided into three distinct components: (1) The 
atheroma, which is closest to the arterial lumen and has a nodular structure consisting mainly 
of macrophage foam cells, (2) the underlying areas of cholesterol crystals, and (3) 
calcification at the outer base of advanced lesions. The development of human 
atherosclerosis, linking the lipoprotein/cholesterol disorder and the inflammatory processes, 
continues for years and decades. Besides contributing to plaque destabilization when falling 
apart in a necrotic fashion, macrophage foam cells secrete extracellular matrix proteases 
(ECM) and collagenases that digest the ECM and collagen fibrils that are enriched in fibrous 
caps, respectively. Vascular smooth muscle cells also secrete these proteolytic enzymes, 
thereby enhancing this destabilizing process. Atheromatous plaques that are susceptible to 
arterial wall breakdown are described as vulnerable plaques and characterized by thin fibrous 
caps, large necrotic areas, and increased number inflammatory cells and molecules (Tabas, 
2010). 
Atherothrombosis 
Atherothrombotic vascular disease (ATVD) is the primary cause of myocardial infarction and 
stroke, which are the main causes of morbidity and mortality in developed countries.  
 
Figure 4 Arterial thrombosis 
The primary trigger of arterial thrombosis is rupture of an atherosclerotic plaque. The 
disruption of the endothelium releases the thrombogenic plaque content, including tissue 
factor, into the lumen of the blood vessel. Platelets will be recruited and aggregate at the 
forming thrombus.  
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The main trigger of thrombosis is the rupture of a vulnerable atherosclerotic plaque. Once an 
atherosclerotic plaque ruptures, thrombogenic material attracts platelets to the site of injury, 
thereby inducing platelet aggregation and an increase of the nascent thrombus. Tissue factor 
(coagulation factor III) is abundantly expressed by various cells in atherosclerotic plaques and 
released into the blood during rupture, thereby activating the coagulation cascade that will 
activate platelets. Activated platelets then release the contents of granules, which further 
promote platelet recruitment, adhesion, aggregation and activation (Figure 4) (Mackman, 
2008). 
Mouse models of atherosclerosis 
Normal wild-type mice do not develop atherosclerosis when kept under normal diet. The 
reason is that wild-type mice have extremely low levels of remnant lipoproteins 
(chylomicrons and IDL remnants). When kept under a high-cholesterol, high-fat diet the 
development of atherosclerosis is strain dependent, e.g. C3H is an atherosclerosis-resistant 
strain, while C57BL/6 is an atherosclerosis-susceptible strain (Paigen et al., 1987). The two 
most abundantly used mouse models to study atherogenesis are apolipoprotein E (ApoE) and 
LDL-Receptor (LDL-R) knockout mice (Ishibashi et al., 1993; Plump et al., 1992; Zhang et 
al., 1992). ApoE-/- mice lack apolipoprotein E, which normally clears remnant lipoproteins 
from the bloodstream through binding to the LDL-Receptor (that is lacking in LDL-R-/- mice) 
or the LDL receptor-related protein (LRP) in hepatocytes. Absence of these molecules leads 
to accumulation of remnant lipoproteins in the blood and thereby to the development of 
atherosclerosis (Breslow, 1996). 
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4.2 Sirtuins and Nε-lysine deacetylation	  
Acetylation of the Nε-lysine residue is a reversible, posttranslational protein modification. 
Histone acetyltransferases (HATs) transfer the acetyl moiety from acetyl coenzyme A to the 
ε-NH3+ groups of internal lysine residues. Addition of this acetyl group neutralizes the 
positive charge and thereby increases hydrophobicity. In addition this modification is able to 
influence the interaction with other proteins as well as other posttranslational modifications, 
such as methylation, ubiquitination and sumoylation. Histone deacetylases (HDACs) promote 
the reversible reaction, the deacetylation of the acetyl-Nε-lysine residue and thereby re-
establish the positive charge of the protein (Kuo and Allis, 1998). Nε-lysine acetylation and 
deacetylation was initially observed in histone proteins, but later on other non-histone proteins 
were also shown to undergo this posttranslational protein modification. 
HDACs are classified into 4 families: Classes I, II, III, and IV. Class III HDACs are also 
called sirtuins. The mammalian sirtuin family consists of 7 HDACs that share a conserved 
catalytic core domain and are expressed ubiquitously (Michan and Sinclair, 2007). Except 
SIRT4, all sirtuins exhibit a nicotinamide adenine dinucleotide (NAD+)-dependent 
deacetylase activity. At least SIRT4, SIRT6 and SIRT7 show an (additional) enzymatic ADP-
ribosyltransferase activity and can transfer the ADP-ribosyl moiety of NAD+ to a target 
protein (Houtkooper et al., 2010; Lavu et al., 2008). Sirtuins reverse Nε-lysine acetylations of 
their target proteins by hydrolyzing one NAD+ and releasing nicotinamide (NAM), a unique 
byproduct called O-acetyl-ADP-ribose (OAADPr), and the deacetylated substrate (Figure 5) 
(Avalos et al., 2005; Denu, 2005; Tanner et al., 2000). Recent studies suggest that OAADPr 
may have biological functions on its own (Taylor et al., 2008). 
SIRT1, SIRT6 and SIRT7 are nuclear deacetylases, with SIRT7 localizing mainly to nucleoli. 
SIRT3, SIRT4, and SIRT5 are localized mainly in mitochondria, whereas SIRT2 is detected 
primarily in the cytoplasm. Nevertheless, SIRT1 and SIRT3 have also been detected in the 
cytoplasm, and some studies suggest that SIRT2 can also be found in the nucleus (Finkel et 
al., 2009; Haigis and Guarente, 2006; Michan and Sinclair, 2007; Taylor et al., 2008). 
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Figure 5 Nε-lysine deacetylation by sirtuins 
Sirtuins deacetylate specific acetylated Nε-lysine residues of their target proteins in a 
reaction that consumes NAD+, and yields the deacetylated protein, NAM, and OAADPr. 
4.3 SIRT1	  
Sir2, the yeast homolog of SIRT1, was discovered as a factor necessary for the transcriptional 
silencing of the silent mating-type loci and telomeric areas in yeast by inducing DNA 
heterochromatization (Gottlieb and Esposito, 1989; Maillet et al., 1996; Rine and Herskowitz, 
1987). Homologues are also found in Escherichia coli, Salmonella typhimurium, 
Caenorhabditis elegans, Drosophila melanogaster, Mus musculus, Macaca mulatta, humans, 
and many other species, showing that the Sir2 family is conserved from bacteria to humans 
(Blander and Guarente, 2004; Brachmann et al., 1995; Frye, 1999; Tsang and Escalante-
Semerena, 1998). 
The finding that extra copies of Sir2 prolong the life span of yeast, while Sir2 deficiency 
caused the opposite (Kaeberlein et al., 1999), drew the attention of many scientists to the 
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Sir2/sirtuin field. Shortly afterwards, it was shown that Sir2 is an NAD+-dependent histone 
deacetylase and that both Sir2 and NAD+ are required for calorie restriction-mediated life 
span extension in yeast (Imai et al., 2000; Lin et al., 2000; Lin et al., 2004b; Lin et al., 2002). 
These findings placed Sir2 into a central position linking the metabolic state of a cell with the 
transcriptional control of gene expression. 
Sir2 homologues and Sir2 activators also regulate life span in Caenorhabditis elegans and 
Drosophila melanogaster (Rogina and Helfand, 2004; Tissenbaum and Guarente, 2001; 
Wood et al., 2004), and it was recently demonstrated that moderate caloric restriction lowers 
the incidence of aging-related deaths in rhesus monkeys (Colman et al., 2009). Nevertheless, 
if sirtuins are directly involved in calorie restriction-mediated lifespan extension remains 
unclear (Baur et al., 2010; Fontana et al., 2010; Kaeberlein, 2010; Kaeberlein and Powers, 
2007). What seems clear, on the other hand, is the central role of SIRT1 as a metabolic 
regulator. The function of many important metabolic proteins is regulated by SIRT1, 
including peroxisome proliferator-activated receptor γ (PPARγ), PPARγ coactivator 1α (PGC-
1α), nuclear factor-κB (NF-κB), Liver X receptor α (LXRα or Nr1h3), and endothelial nitric 
oxide synthase (eNOS) (Lagouge et al., 2006; Li et al., 2007; Mattagajasingh et al., 2007; 
Picard et al., 2004; Rodgers et al., 2005; Yeung et al., 2004). Interestingly, some of these 
molecules have also been shown to play a direct or indirect role in atherogenesis (Kim et al., 
2007b; Knowles et al., 2000; Thurberg and Collins, 1998; Tontonoz and Spiegelman, 2008). 
Several studies propose that SIRT1 could exert a protective role in the cardiovascular system: 
In rat aortic rings prepared ex vivo SIRT1 improves endothelial dysfunction by activating 
eNOS (Mattagajasingh et al., 2007), suggesting that SIRT1 may prevent an early atherogenic 
event. SIRT1 regulates angiogenesis and ischemia-induced neovascularization in zebrafish 
and mice via deacetylation of the anti-angiogenic transcription factor Foxo1 (Potente et al., 
2007). Cholesterol efflux, an event that is important in later stages of atherogenesis, may also 
be influenced by SIRT1. It was demonstrated that SIRT1 regulates the transcriptional activity 
of LXRα via direct deacetylation in in vitro and ex vivo experiments using macrophages (Li 
et al., 2007).  
Given the multiple targets of SIRT1, it is likely that other targets apart from eNOS, Foxo1, 
and LXR and the involved mechanisms are regulated by SIRT1 in atherogenesis. In particular, 
the role of SIRT1 in monocyte adhesion, macrophage infiltration as well as lipid uptake and 
foam cell formation has not yet been investigated. During the course of this PhD thesis some 
studies from other groups as well as the results of our studies demonstrated that SIRT1 is 
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indeed involved in different processes in atherogenesis. The consensus and discrepancy 
between these studies will be discussed. 
4.4 PGC-1α 
One of the best-characterized deacetylation targets of SIRT1 is PGC-1α (Rodgers et al., 
2005). PGC-1α is an important cofactor in the transcriptional regulation of genes encoding 
metabolic enzymes and mitochondrial proteins (Lin et al., 2005). PGC-1α was the first 
described member of the small PGC-1 family of coactivators (Puigserver et al., 1998). Other 
members of this protein family are PGC-1β and PGC-related coactivator (PRC). NAD+-
dependent deacetylation by SIRT1 activates PGC-1α, which in turn modulates the expression 
of many genes, including genes with a crucial role in glucose homeostasis, oxidative 
phosphorylation and mitochondrial biogenesis (Lagouge et al., 2006; Rodgers et al., 2005). 
A well characterized metabolic signaling cascade involves the 5'-AMP-activated protein 
kinase (AMPK), changes in intracellular NAD+ levels, SIRT1, and PGC-1α (Canto and 
Auwerx, 2009). Cells that are subjected to metabolic stress that interferes with ATP synthesis, 
develop an increased ADP:ATP ratio. The adenylate kinase, which catalyzes the 
interconversion of adenine nucleotides, further amplifies this effect by increasing the ratio of 
AMP:ATP. Enhanced intracellular levels of AMP then activate the AMPK, which blocks 
anabolic processes requiring energy and favors catabolic processes generating ATP (Hardie, 
2007). A result of this AMPK-mediated metabolic adaptation is an increase in the 
NAD+:NADH ratio (Canto et al., 2009). Increased levels of NAD+ will then activate SIRT1, 
which in turn deacetylates and activates PGC-1α and other important transcriptional 
regulators that help the cell to adapt to the metabolic stress (Canto et al., 2010). Therefore, it 
could well be that atheroprotective effects of SIRT1 (or AMPK) might act via PGC-1α 
activation. 
However, PGC-1α may also affect atherogenesis independently of SIRT1. PGC-1α interacts 
with many different transcription factors, some of which play important roles in metabolic 
processes, such as PPARα, PPARβ/δ, PPARγ, LXRα/β, GR, and Foxo1 (Kressler et al., 2002; 
Oberkofler et al., 2003; Puigserver et al., 2003; Puigserver and Spiegelman, 2003; Vega et al., 
2000; Wang et al., 2003; Yoon et al., 2001). Overexpression of PGC-1α in human aortic 
endothelial cells (HAECs) and human aortic smooth muscle cells (HASMCs) prevents TNF-
α-induced ROS production, mitochondrial NAD(P)H oxidase activity, and the expression of 
the pro-inflammatory molecules MCP-1 and VCAM-1 (Kim et al., 2007b). Furthermore, two 
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genetic correlation studies strengthen the possible correlation between PGC-1α and 
atherogenesis: Xie et al. reported a correlation between the G482S and +2962A/G 
polymorphisms of the PGC-1α gene and severe hypertension (Xie et al., 2007), and Zhang et 
al. showed a correlation between PGC-1α G482S polymorphism and the prevalence of 
coronary artery disease (Zhang et al., 2008b). 
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4.4 Hypotheses and specific aims 
Based on the published observations described above, we hypothesized that both SIRT1 and 
PGC-1α are atheroprotective proteins (Figure 6):  
• SIRT1 protects against atherosclerosis by activating atheroprotective molecules, such 
as eNOS, hence improving endothelial function, and/or by inhibiting pro-atherogenic 
proteins and pathways, such as NF-κB signaling, thus preventing endothelial 
inflammation. 
• PGC-1α prevents atherosclerosis by mediating SIRT1-dependent effects or SIRT1-
independent effects, such as suppression of endothelial adhesion molecule expression. 
 
Figure 6 PhD hypotheses 
Activation or overexpression of SIRT1 leads to deacetylation of various target proteins. We 
hypothesized that SIRT1-dependent deacetylation activates anti-atherogenic targets (e.g., 
PGC-1α and eNOS) and deactivates pro-atherogenic protein and pathways (e.g., NF-κB). 
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Specific aims 
Based on these hypotheses, we formulated following research aims: 
Aim 1 – Characterize the role of SIRT1 in atherogenesis: Comparison of 20-week-old 
male ApoE-/- SIRT1+/+ and ApoE-/- SIRT1+/- mice kept on a high-cholesterol diet for 12 weeks. 
Aim 2 – Determine the role of SIRT1 in arterial thrombosis: Analyze the expression of 
tissue factor upon genetic and pharmacological SIRT1 modulation in vitro in HAECs and in 
pharmacological approaches in C57BL/6 mice in vivo. 
Aim 3 – Asses the role of PGC-1α in atherogenesis: Comparison of 20-week-old male 
ApoE-/- PGC-1α+/+ and ApoE-/- PGC-1α-/- mice kept on a high-cholesterol diet for 12 weeks. 
General approach to study atherosclerosis in mice (Figure 7): 
 
Figure 7 Time point for the most important in vivo and ex vivo experiments 
6 to 8-week-old male mice fed a normal diet were used for LPS injection assays to study the 
effect of acute NF-κB signaling activation or to isolate thioglycolate-elicited peritoneal 
macrophages for ex vivo assays. Endothelium-dependent vascular function and 
atherosclerosis were studied in 20-week-old male mice that were fed a 1.25% high-
cholesterol diet for 12 weeks. Besides quantifying plaques in the thoraco-abdominal aortae 
en face, advanced plaque parameters and inflammatory burden were assessed in cross 
sections of plaques from the aortic sinus and/or aortic arch. 
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5	  Results	  
Overview of research articles 
5.1 SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. 
Stein, S., Lohmann, C., Schäfer, N., Hofmann, J., et al. 
Eur Heart J. 2010 Apr 23. Epub ahead of print. 
 
5.2 SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/- 
mice.  
Stein, S., Schafer, N., Breitenstein, A., Besler, C., et al. 
Aging (Albany NY). 2010; 2(6):353-360. 
 
5.3 Sirt1 inhibition induces in vivo arterial thrombosis and tissue factor expression in 
activated human endothelial cells. 
Breitenstein, A., Stein, S., Holy, E.W., Camici, G.G., et al. 
Cardiovasc Res. 2010 Nov 21. Epub ahead of print. 
 
5.4 ApoE-/- PGC-1a-/- mice display reduced IL-18 levels and do not develop enhanced 
atherosclerosis. 
Stein, S., Lohmann, C., Handschin, C., Stenfeldt, E., et al. 
PLoS ONE. 2010; 5(10): e13539. 
 
 
 
 
 
- 28 -
 
 
Contribution to other published projects within the PhD thesis period 
Heart-infiltrating prominin-1+/CD133+ progenitor cells represent the cellular source of TGF-
β-mediated cardiac fibrosis in experimental autoimmune myocarditis 
 Authors: Gabriela Kania, Przemyslaw Blyszczuk, Sokrates Stein, Alan 
Valaperti, Davide Germano, Stephan Dirnhofer, Lukas Hunziker, 
Christian Matter, Urs Eriksson 
 Journal: Circ Res. 2009; 105(5):462-70. 
 DOI: 10.1161/CIRCRESAHA.109.196287 
 PMID: 19628793 
 Comment in: Madeleine W. Cunningham 
Circ Res. 2009 Aug 28;105(5):403-5 
 Contribution: Performance of Phospho-Smad2 and Smad2/3 Western blots on murine 
heart lysates. 
Atherosclerotic Mice Exhibit Systemic Inflammation in Periadventitial and Visceral Adipose 
Tissue, Liver, and Pancreatic Islets 
 Authors: Christine Lohmann, Nicola Schäfer, Tobias von Lukowicz, M. A. 
Sokrates Stein, Jan Boren, Sabine Rütti, Walter Wahli, Marc Y. 
Donath, Thomas F. Lüscher, Christian M. Matter 
 Journal: Atherosclerosis. 2009; 207(2):360-7. 
 DOI: 10.1016/j.atherosclerosis.2009.05.004 
 PMID: 19481752 
 Contribution: Performance and analyses of real-time PCRs of transcripts regulating 
lipid metabolism. 
Editorial - A dual role of CD4+ T cells in adipose tissue? 
 Authors: Christian M. Matter & M. A. Sokrates Stein 
 Journal: Circ Res. 2009; 104(8):928-30 
 DOI: 10.1161/CIRCRESAHA.109.197004 
 PMID: 19390060 
 Comment on: Ariane Sultan et al. 
Circ Res. 2009 Apr 24;104(8):961-8. 
 Contribution: Writing the editorial 
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5.1 SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis 
 
 Authors: Sokrates Stein, Christine Lohmann, Nicola Schäfer, Janin Hofmann, 
Lucia Rohrer, Christian Besler, Karin M. Rothgiesser, Burkhard Becher, 
Michael O. Hottiger, Jan Borén, Michael W. McBurney, Thomas F. 
Lüscher and Christian M. Matter 
 Journal: European Heart Journal. 2010 Apr 23. Epub ahead of print. 
 DOI: 10.1093/eurheartj/ehq107 
 PMID: 20418343 
 Contribution: Design and analyses of all experiments; performance of most 
experiments; writing the manuscript. 
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SIRT1 decreases Lox-1-mediated foam cell
formation in atherogenesis
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Aims Endothelial activation, macrophage infiltration, and foam cell formation are pivotal steps in atherogenesis. Our aim in
this study was to analyse the role of SIRT1, a class III deacetylase with important metabolic functions, in plaque
macrophages and atherogenesis.
Methods
and results
Using partial SIRT1 deletion in atherosclerotic mice, we demonstrate that SIRT1 protects against atherosclerosis by
reducing macrophage foam cell formation. Peritoneal macrophages from heterozygous SIRT1 mice accumulate more
oxidized low-density lipoprotein (oxLDL), thereby promoting foam cell formation. Bone marrow-restricted SIRT1
deletion confirmed that SIRT1 function in macrophages is sufficient to decrease atherogenesis. Moreover, we
show that SIRT1 reduces the uptake of oxLDL by diminishing the expression of lectin-like oxLDL receptor-1 (Lox-1)
via suppression of the NF-kB signalling pathway.
Conclusion Our findings demonstrate protective effects of SIRT1 in atherogenesis and suggest pharmacological SIRT1 activation
as a novel anti-atherosclerotic strategy by reducing macrophage foam cell formation.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords SIRT1 † Macrophage foam cell † Atherogenesis
Introduction
Atherosclerosis is a chronic inflammatory disease that results from
interaction between oxidized low-density lipoprotein (oxLDL),
activated endothelial cells, monocyte-derived macrophages, T
cells, and the arterial wall. Activated endothelial cells express
adhesion molecules, e.g. vascular cell adhesion molecule 1
(VCAM-1) and intercellular adhesion molecule-1 (ICAM-1),
which attract and recruit blood monocytes to the vessel wall.
These monocytes differentiate into macrophages and infiltrate to
the sub-endothelial space where they release and respond to
inflammatory mediators such as tumour necrosis factor-a
(TNFa), VCAM-1, and interleukins (IL). Eventually, these inflamma-
tory macrophages ingest oxLDL via scavenger receptors, such as
scavenger receptor-A (SR-A), CD36 or lectin-like oxLDL receptor
1 (Lox-1), becoming foam cells, and thereby promoting plaque
formation.1
Sir2 is an NAD-dependent class III deacetylase that was found to
increase lifespan in yeast.2 Its mammalian orthologue SIRT1 senses
caloric restriction, improves insulin secretion in pancreatic beta
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cells, and reduces accumulation of fatty acids in white adipose
tissue (WAT).3–5 Various targets of SIRT1 have been character-
ized, including PPARg coactivator 1a (PGC-1a), nuclear factor
kB (NF-kB), p53, FOXO transcription factors, and endothelial
nitric oxide synthase (eNOS).6–13 Interestingly, many of these
targets that are critically involved in regulating metabolism have
also been shown to play a role in atherogenesis.14–18 However,
little is known about the relevance of SIRT1 in the latter.
In atherogenesis, chronic endothelial dysfunction is a trigger of
plaque formation,19 and endothelial SIRT1 overexpression has been
shown to prevent atherosclerosis by improving vascular function.20
Nevertheless, the relevance of SIRT1 on the cellular and molecular
events governing atherogenesis is unknown. As multiple targets of
SIRT1 may play a role in plaque formation, it is likely that eNOS is
not the only mechanism by which SIRT1 prevents atherogenesis. In
particular, the role of SIRT1 in monocyte adhesion, macrophage infil-
tration, lipid uptake, and foam cell formation remains to be
determined.
To investigate the role of SIRT1 in these cellular and molecular
processes, we compared hypercholesterolaemic ApoE2/2
SIRT1+/+ with ApoE2/2 SIRT1+/2 mice. These mice have an
SIRT1 haploinsufficiency, but do not display the autoimmune and
dysmorphic phenotype of SIRT12/2 mice.21,22
Methods
Animals
SIRT1 knockout mice on a 129 background22 were crossed into
ApoE2/2 C57BL/6 mice23 to generate ApoE2/2 SIRT1+/2 mice and
ApoE2/2 SIRT1+/+ littermates. Of those, male mice were fed a high-
cholesterol diet (1.25% total cholesterol, Research Diets) for 12
weeks starting at the age of 8 weeks. Because the few ApoE2/2
SIRT12/2 mice showed a similar dysmorphic phenotype as SIRT12/2
mice,21,22 we did not use them in this study. All animal procedures
were approved by the local animal committee and performed in
accordance with our institutional guidelines.
Bone marrow transplantation
Bone marrow donor mice were ApoE2/2 SIRT1+/2 (n ¼ 3; pooled) and
ApoE2/2 SIRT1+/+ (n ¼ 3; pooled) mice, and recipients pure ApoE2/2
mice (from Jackson Laboratories). Donor mice were split—
dose-irradiated under SPF conditions in filter cages with a total
irradiation of 1100 rad.24 Recipient mice were injected intravenously
with 106 bone marrow cells (ApoE2/2 SIRT1+/27 ApoE2/2 mice;
ApoE2/2 SIRT1+/+6 ApoE2/2 mice). Transplanted mice recovered
for 5 weeks and were then fed a high-cholesterol diet for 11 weeks.
Lipoprotein uptake
RAW 264.7 and thioglycolate-elicited peritoneal macrophages were
starved for 48 h and then incubated with 10 mg/mL oxLDL for 2 h at
378C/5% CO2. After washing away unspecifically bound LDL, cells
were fixed and stained with Oil red O (ORO). Experiments were
done twice with six independent pools isolated from six mice of
each genotype, ORO staining analysed using a light microscope and
quantified using analySIS. Low-density lipoprotein uptake was quanti-
fied as the ratio of the percentage of the ORO-positive area divided
by the percentage of the total cell area in at least 150 cells per geno-
type. For CD36 blocking studies, RAW 264.7 macrophages were first
pre-stimulated for 5 h with 10 ng/mL murine TNFa, and then pre-
incubated with 2 mg/mL mouse anti-CD36 (Cascade Bioscience)
before adding 10 mg/mL oxLDL over night.
Cell culture
Murine RAW 264.7 cells (Mouse leukaemic monocyte macrophage cell
line) were treated with 200 mM splitomicin (Sigma-Aldrich) to perform
cholesterol efflux and oxLDL uptake studies. RAW 264.7 cells were
stimulated for with 10 ng/mL murine TNFa for 5 h. SIRT12/2 mouse
embryonic fibroblasts (MEF)25 were kindly provided by Frederick
W. Alt (Harvard University, Boston, MA, USA), and RelA/p652/2
MEF with reconstituted wt-RelA/p65 or non-acetylatable RelA/p65
were described previously.26
Plasmid and siRNA transfection
Transient transfection of pcDNA3.1::SIRT1 or siRNA into RAW 264.7
or MEF were done with lipofectamin 2000 or lipofectamin RNAi MAX
(both Invitrogen). The oligos used for SIRT1-siRNA have been
described previously.5
Immunohistochemistry and
immunocytochemistry
Serial cryosections from the aortic sinus were stained with ORO, rat
anti-CD68, rat anti-CD3 (Abcam), rat anti-CD31, rabbit anti-SIRT1
(Upstate/Millipore). Means were taken from n ¼ 6 different mice eval-
uating six serial cryosections/tissue from each mouse. Thoraco-
abdominal aortae were fixed and plaques stained with ORO. Collagen,
fibrous cap thickness, and necrotic core size were analysed by Elastica
van Gieson and Massons trichrome stainings. Cell death was assessed
with the terminal deoxyribonucleotidyl transferase-mediated dUTP
nick-end labelling kit (Roche).
RNA and protein analysis
Total RNA isolated from proximal aortae was extracted with TRIZOL
(Invitrogen), reverse transcribed, and the cDNA quantified by SYBR
green qPCR using specific primers. For protein analysis, aortic tissue
lysates were blotted and incubated with rabbit anti-SIRT1 (Upstate/
Millipore), rabbit anti-eNOS, rabbit anti-phospho-eNOS (Ser1177).
Cholesterol efflux
For cholesterol efflux experiments, RAW 264.7 cells were labelled
with 2 mCi/mL [1,2-3H]cholesterol (Perkin Elmer) for 24 h. Following
the labelling period, cells were washed and allowed to equilibrate over-
night in DMEM containing 0.2% BSA supplemented with cholesterol in
the presence or absence of 0.1 mM splitomicin together with 0.3 mM
8-Br-cAMP or 22(R)-HC and 9-cisRA (Sigma). After 24 h stimulation,
cells were washed and incubated for 6 h in DMEM containing 0.2%
BSA in the presence or absence of 28 mg/mL lipid-free apoA-I. The
radioactivity recovered in the culture medium and cell lysates was
measured. The apoA-I-mediated cholesterol efflux was calculated as
the percentage of total [1,2-3H]cholesterol released into the
medium after subtracting the values obtained in the absence of
apoA-I. The cholesterol efflux assays were performed in duplicates
with three pairs per treatment group.
Plasma lipids and cytokines
Total plasma cholesterol, triglycerides, and free fatty acids were ana-
lysed using TR13421, TR22421 (Thermo Electron, Inc.), and 994–
75409 (Wako Chemicals). The lipid distribution in plasma lipoprotein
fractions was assessed by fast-performance liquid chromatography gel
filtration with a Superose 6 HR 10/30 column (Pharmacia).27 Plasma
values of VCAM-1 (MVC00) and ICAM-1 (MIC100; R&D) were
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determined using ELISA, and TGF-b, IFNg, IL-6, IL-10, and mKC using
multiplex array systems (Becton, Dickinson and Company).
Flow cytometry
For blood and spleen FACS analyses, single cell suspensions were incu-
bated with antibodies against CD4, CD8, B220, CD11c, CD11b,
CD62L, CD44, and CD25 (BD Pharmingen) and then cells were ana-
lysed with a FACSCantoII (BD Pharmingen) and FACSDiva software.
Post-acquisition analysis was done with FACSDiva (BD Pharmingen)
or FlowJo7 software (Tree Star).
Statistical analysis
Data are presented as mean+ SEM. The en face ORO quantifications
were analysed with a non-parametric Mann–Whitney U-test. Statistical
significance of differences was calculated using an ANOVA with post
hoc Tukey’s test or Student unpaired t-test. Significance was accepted
at the level of P, 0.05.
Results
SIRT1 protects against atherosclerosis
To address the role of SIRT1 in atherogenesis, we compared SIRT1
expression in aortic lysates obtained from atherosclerotic
ApoE2/2 and normal wild-type (WT) mice. Aortic SIRT1 protein
expression was lower in ApoE2/2 than in WT mice (see Sup-
plementary material online, Figure S1A), suggesting a protective
role of SIRT1 in atherogenesis. In order to establish a cause–
effect relationship between SIRT1 expression and atherosclerosis,
we applied genetic deletion of SIRT1 in atherosclerotic mice. For
this purpose, we compared 20-week-old male ApoE2/2
SIRT1+/+ and ApoE2/2 SIRT1+/2 mice that were kept on a high-
cholesterol diet for 12 weeks (see Supplementary material
online, Figure S2A). Of note, SIRT1 expression is only slightly
reduced in WT mice treated with a high-cholesterol diet (see
Figure 1 SIRT1 protects mice against atherosclerosis. (A) En face Oil red O (ORO) staining of thoraco-abdominal aortae and quantifications
of plaque area. n ¼ 9, ApoE2/2 SIRT1+/+(B); n ¼ 11, ApoE2/2 SIRT1+/2(A). (B) Representative images for Massons trichrome and Elastica van
Gieson stainings from animals with comparable plaque sizes. Magnification: X 40. *P, 0.05.
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Supplementary material online, Figure S1B). To examine any SIRT1
compensation for the missing SIRT1 allele, we assessed
SIRT1 expression in aortic lysates of the two genotypes. Aortic
SIRT1 protein in ApoE2/2 SIRT1+/2 mice amounted to about
60% of protein in ApoE2/2 SIRT1+/+ mice (see Supplementary
material online, Figure S1C). Importantly, en face plaque quantifi-
cations in thoraco-abdominal aortae and in serial cross sections
of aortic roots revealed fewer atherosclerotic plaques in
ApoE2/2 SIRT1+/+ compared with ApoE2/2 SIRT1+/2 mice
(Figures 1A and 2). Massons trichrome and van Gieson stainings
revealed that total collagen content, necrotic core size, and
fibrous cap thickness did not differ between the two groups
(Figure 1B, see Supplementary material online, Figure S1D–F). No
difference was observed in the amount of apoptotic cells (see Sup-
plementary material online, Figure S1F). These findings indicate that
endogeneous SIRT1 protects against atherosclerosis.
Accumulation of plaque macrophages
and T cells is reduced by SIRT1
Accumulation of macrophages and T cells in the subintimal space
plays a central role in atherogenesis.1 Our analyses revealed
increased accumulation of macrophages and T cells in athero-
sclerotic plaques of ApoE2/2 SIRT1+/2 compared with ApoE2/2
SIRT1+/+ mice (Figure 2). SIRT1 staining in aortae of healthy WT
mice or ApoE2/2 mice under normal diet showed that SIRT1 is
expressed in smooth muscle and endothelial cells (see
Supplementary material online, Figure S3A). In diseased aortae
from ApoE2/2 mice under high-cholesterol diet, SIRT1 is also
expressed in cells within the plaques (see Supplementary material
online, Figure S3A). Double stainings revealed that SIRT1 is
expressed in both plaque endothelial cells and macrophages in dis-
eased ApoE2/2 aortae (see Supplementary material online, Figure
S3B).
SIRT1 in macrophages is sufficient to
reduce foam cell formation and
atherogenesis
We observed no difference neither in fasted nor fed plasma
glucose or insulin levels, total body or epididymal fat weight (see
Supplementary material online, Figure S4) and found no difference
in total cholesterol and its subfractions between ApoE2/2
SIRT1+/+ and ApoE2/2 SIRT1+/2 mice (see Supplementary
material online, Figure S5 and Table S1). Further, plasma cytokine
levels were similar in the two genotypes (see Supplementary
material online, Table S2). Since inflammatory factors from WAT
may enhance atherogenesis,28,29 we examined the expression of
several adipokines and adipose-derived hormones in epididymal
WAT. Expression of Adiponectin (Adipoq), Leptin, Visfatin (Nampt),
Chemerin (Rarres2), Resistin (Retn) were equivalent, whereas
expression of Plasminogen activator inhibitor 1 (PAI-1 or Serpine1)
was slightly, but not significantly elevated in ApoE2/2 SIRT1+/2
compared with ApoE2/2 SIRT1+/+ epididymal WAT (see
Figure 2 SIRT1 deletion increases macrophage and T-cell accumulation in plaques. Immunohistochemistry with quantifications of Oil red O
(ORO), CD68, andCD3 (arrows) on plaques from aortic sinus. Magnifications:Oil redO, CD68:×40; CD3:×400. n ¼ 6 per genotype. *P, 0.05.
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Supplementary material online, Figure S6). These data do not
exclude a contribution of systemic inflammatory factors such as
WAT, but suggest that the damaging effects of partial SIRT1
deficiency are mainly mediated via inflammatory cells localized in
plaques.
Therefore, we focused on the role of SIRT1 in macrophages.
Foam cell formation is a crucial step in atherogenesis.1 We
observed no difference in basal LDL uptake in peritoneal-elicited
macrophages from ApoE2/2 SIRT1+/2 compared with ApoE2/2
SIRT1+/+ mice, but found enhanced uptake upon stimulation
with oxLDL (Figure 3A). Pharmacological inhibition of SIRT1 with
splitomicin in RAW 264.7 macrophages showed a trend towards
increasing oxLDL uptake (see Supplementary material online,
Figure S7). Consistently, siRNA-induced SIRT1 knockdown
increased uptake of oxLDL in RAW 264.7 macrophages compared
with control cells (Figure 3B and C ). To study a potential role of
CD36 in oxLDL uptake, we blocked CD36-mediated oxLDL
uptake using an anti-CD36 antibody in scrambled or
SIRT1-siRNA-treated macrophages. Neutralization of CD36
decreased uptake of oxLDL by 50% compared with non-
neutralized cells (Figure 3C). A higher elevation of oxLDL uptake
was observed in SIRT1-siRNA-treated macrophages with
additional CD36 neutralization, but did not reach significance
difference compared with any other group (Figure 3C). These
Figure 3 SIRT1 reduces foam cell formation. (A) Increased uptake of oxLDL in peritoneal thioglycolate-elicited macrophages from ApoE2/2
SIRT1+/2 compared with ApoE2/2 SIRT1+/+ mice. oxLDL uptake is given as the ratio of the percentage of ORO-positive area divided by the
percentage of total cell area in at least 150 cells per genotype. (B) siRNA-induced SIRT1 knockdown increases uptake of oxLDL in RAW 264.7
macrophages compared with scr-siRNA-treated cells. (C) siRNA-mediated SIRT1 silencing in 5 h TNFa-pretreated RAW 264.7 macrophages:
left panel, expression of Lox-1; right panel, uptake of oxLDL in neutralizing anti-CD36 antibody-treated cells. *P, 0.05. ***P, 0.001. Magni-
fications: ×400.
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data suggest that SIRT1 exerts CD36-dependent and -independent
effects in oxLDL uptake.
To examine whether an SIRT1-dependent mechanism in macro-
phages accounts for decreased atherosclerosis in vivo, we per-
formed bone marrow transplantation experiments. Bone marrow
from ApoE2/2 SIRT1+/2 or ApoE2/2 SIRT1+/+ mice was trans-
planted into irradiated 6-week-old ApoE2/2 mice (see Supplemen-
tary material online, Figure S2B), respectively. Flow cytometry
analyses of blood and spleen samples from transplanted mice
revealed an increased number of blood monocytes of ApoE2/2
recipient mice receiving ApoE2/2 SIRT1+/2 bone marrow cells,
but no proportional difference in T-cell subtypes, MHCII+ cells,
B cells or macrophages (see Supplementary material online,
Figure S8). Chimeric ApoE2/2 recipient mice receiving ApoE2/2
SIRT1+/2 bone marrow showed more atherosclerotic lesions
compared with mice transplanted with ApoE2/2 SIRT1+/+ bone
marrow (Figure 4). These findings support the notion that SIRT1
function in macrophages is sufficient to decrease atherogenesis.
Deacetylation of RelA/p65 by SIRT1
diminishes Lox-1 expression
Active uptake of modified cholesterol in macrophages is mainly
regulated by SR-A, SR-B, CD36, and Lox-1,30 whereas cholesterol
efflux is driven by ATP-binding cassette transporters.31 Expression
of CD36, SR-A, and SR-B was not altered (see Supplementary
material online, Figure S9), whereas Lox-1 expression was higher
in ApoE2/2 SIRT1+/2 aortic lysates (Figure 5A). Because expression
of Lox-1 in SIRT1-siRNA-treated macrophages was increased
(Figure 3C), we planned to study the SIRT1–Lox-1 pathway
more in detail. Deletion of Lox-1 has been shown to reduce ather-
osclerosis in mice.32 Since Lox-1 is an NF-kB target33 and SIRT1
deacetylates RelA/p65 in murine macrophages,34 we compared
Lox-1 RNA levels in TNFa-stimulated RAW 264.7 cells pretreated
with splitomicin. We observed an increase in Lox-1 expression in
splitomicin-treated macrophages compared with untreated
control cells (Figure 5B). These data suggest that SIRT1 suppresses
NF-kB signalling in macrophages, thereby reducing Lox-1
expression and oxLDL uptake.
To get more insight into the molecular events underlying SIRT1-
dependent NF-kB deacetylation in murine cells, we analysed
SIRT1 expression in different MEF cell lines. Ectopic expression of
SIRT1 in SIRT12/2 MEF reduced Lox-1 expression upon TNFa treat-
ment (Figure 5C). In RelA/p652/2 MEF with reconstituted wt-RelA/
p65 expression,26 siRNA-induced SIRT1 knockdown enhanced
Lox-1 expression upon TNFa stimulation. In contrast, SIRT1-siRNA
had no effect on Lox-1 expression in TNFa-stimulated RelA/p652/2
MEF with reconstituted non-acetylatable K310R-mutant-RelA/p6526
(Figure 5D). These data show that SIRT1-dependent deacetylation of
RelA/p65 at K310 is sufficient to reduce Lox-1 gene expression.
Several reports show a link between Lox-1 and matrix metallo-
proteinases (MMPs) that are expressed and secreted by human
endothelial cells, including the collagenase MMP1, stromelysin-1
(MMP3), the membrane type 1 MMP (MT1-MMP or MMP14),
and the tissue inhibitor of metalloproteinase 3 (TIMP3).35–38 To
investigate if metalloproteinase expression is affected by SIRT1,
we quantified aortic expression of MMP13, MMP3, MMP8,
MMP9,MMP14, and TIMP3. No significant change in the expression
of these MMPs was observed in ApoE2/2 SIRT1+/2 compared with
ApoE2/2 SIRT1+/+ aortae (see Supplementary material online,
Figure S10), indicating that the phenotype of ApoE2/2 SIRT1+/2
mice is not related to SIRT1–Lox-1-mediated expression of MMPs.
Atheroprotective effects of SIRT1 do not
affect cholesterol efflux
When examining cholesterol efflux, we found that expression of
ABCA1 was not altered in aortic lysates from ApoE2/2 SIRT1+/2
compared with ApoE2/2 SIRT1+/+ mice (see Supplementary
material online, Figure S11A). Similarly, expression levels of ABCA1
and ABCG1 were not different in peritoneal macrophages from
ApoE2/2 SIRT1+/+ and ApoE2/2 SIRT1+/2 mice (see Supplemen-
tary material online, Figure S11B). Cholesterol efflux assays in
RAW 264.7 macrophages treated with splitomicin revealed no
ApoA-I-dependent changes (see Supplementary material online,
Figure S11C). Furthermore, we detected no difference in aortic
expression of the ABCA1 regulators LXRa, PPARg, or its coactiva-
tor PGC-1a (PPARg coactivator 1a) (see Supplementary material
online, Figure S11D–F). These data suggest that aortic cholesterol
efflux is not affected by SIRT1 in atherosclerotic mice.
Figure 4 SIRT1 function in macrophages is sufficient to
decrease atherogenesis. Chimeric ApoE2/2 mice that received
ApoE2/2 SIRT1+/2 (n ¼ 7) bone marrow cells develop more
atherosclerosis than those which received ApoE2/2 SIRT1+/+
(n ¼ 5) bone marrow cells. *P, 0.05.
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Discussion
Recently, SIRT1 has been shown to decrease atherosclerosis by
improving endothelium-dependent vascular function in ApoE2/2
mice with an endothelial SIRT1 overexpression that were kept
on a high-fat diet.20 Our study shows that endogenous SIRT1 pre-
vents macrophage foam cell formation in atherogenesis indepen-
dently of systemic lipid levels. We demonstrate that loss of a
single SIRT1 allele in ApoE2/2 SIRT1+/2 mice is sufficient to
increase plaque formation.
Macrophage-derived foam cell formation is enhanced upon a
relative increase in cholesterol uptake or by a defective cholesterol
efflux, respectively.39 Our in vitro foam cell assay reveals that SIRT1
activation diminishes oxLDL uptake in peritoneal macrophages.
Among the receptors that may account for this increased LDL
uptake by macrophages, we identified Lox-1 to be critically
involved: SIRT1 inhibits TNFa-induced expression of Lox-1 in
macrophages. In fact, the Lox-1 promoter contains NF-kB binding
sites and is expressed upon TNFa stimulation.33 Using RelA/
p652/2 MEF, we could further show that the deacetylation of
RelA/p65 by SIRT1 suppresses Lox-1 expression. We acknowledge
that the final proof of a Lox-1-mediated effect on foam cell for-
mation would require additional evidence from genetic
loss-of-function or neutralizing antibody experiments. These ques-
tions need to be addressed in future studies.
To test whether an SIRT1-dependent mechanism in bone
marrow-derived cells accounts for the increase in atherosclerosis
in vivo, we performed bone marrow transplantation experiments.
Chimeric ApoE2/2 mice receiving ApoE2/2 SIRT1+/2 bone
marrow showed increased atherosclerotic plaques compared
with mice receiving ApoE2/2 SIRT1+/+ bone marrow. These find-
ings demonstrate that partial SIRT1 deletion in bone marrow-
derived macrophages is sufficient to enhance atherogenesis.
The role of NF-kB in plaque macrophages and lipoprotein
uptake in atherogenesis is controversial. Disruption of NF-kB sig-
nalling by partial IKK2 deletion in macrophages increased athero-
sclerosis.40 Conversely, studies using macrophage-specific p50
deletion or a dominant-negative IkBa mutant to disrupt NF-kB sig-
nalling, resulted in smaller atherosclerotic lesions and diminished
uptake of lipoproteins.41,42 Since NF-kB and its transcriptional
activity are tightly regulated,43,44 pharmacological modulation of
an upstream regulator of NF-kB seems more promising in prevent-
ing atherogenesis than direct NF-kB modulation.45 Our study
shows that SIRT1 might be an attractive modulator, since its inter-
ference with the NF-kB signalling pathway exerts beneficial effects
on plaque formation.
Several reports suggest that other SIRT1 targets may also con-
tribute to atherogenesis. For instance, PPARg, a key transcription
factor in adipocyte differentiation, plays a pivotal role in macro-
phages and modulates the extent of atherosclerosis.14 Both
PPARg and its target LXR are regulated by SIRT1 in adipocytes
and macrophages.5,46 Interestingly, Li et al.46 showed reduced
cholesterol efflux in primary macrophages from SIRT12/2 com-
pared with SIRT1+/+ mice. We could neither observe a difference
Figure 5 Deacetylation of RelA/p65 by SIRT1 diminishes Lox-1 expression. (A) Aortic Lox-1 expression is increased in ApoE2/2 SIRT1+/2 com-
pared with ApoE2/2 SIRT1+/+ mice. (B) Lox-1 expression is higher in 5 h TNFa-stimulated RAW 264.7 macrophages pretreated with 200 mM
splitomicin (Splito) compared with untreated cells (nt). (C) Ectopic SIRT1 expression in SIRT12/2 MEF reduces Lox-1 expression. (D) In RelA/
p652/2 MEF with reconstituted wt-RelA/p65, siRNA-mediated SIRT1 knockdown enhances Lox-1 expression upon 5 h TNFa stimulation,
whereas no effect is observed in RelA/p652/2 MEF with a reconstituted mutated, non-acetylatable K310-RelA/p65. *P, 0.05; ***P, 0.001.
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in the aortic expression of ABCA1, ABCG1, PPARg, or LXRa nor
an ApoA-I-dependent decrease in cholesterol efflux upon splitomi-
cin treatment in RAW 264.7 macrophages. Possibly, the effect of a
single missing SIRT1 allele is not sufficient to affect cholesterol
efflux in atherosclerotic mice.
Taken together, our results reveal a novel mechanism by which
SIRT1 prevents atherogenesis: SIRT1 suppresses NF-signalling by
deacetylating RelA/p65, thereby reducing Lox-1 expression and
diminishing uptake of oxLDL and foam cell formation. Given the
availability of specific SIRT1-activating drugs that are being tested
in clinical trials in patients with type 2 diabetes, pharmacological
activation of SIRT1 may also become an attractive anti-atherogenic
strategy by preventing macrophage foam cell formation.47
Supplementary material
Supplementary material is available at European Heart Journal
online.
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SUPPLEMENTARY FIGURES 
 
Supplemental Figure 1. Correlation between SIRT1 and atherogenesis. (A) Protein 
expression of SIRT1 and α-tubulin in ApoE-/- and WT aortic lysates. n=6 per genotype. (B) 
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SIRT1 mRNA levels in aortic tissue of wild-type mice treated a normal or high-cholesterol 
diet. n=4 per treatment group. (C) ApoE-/- SIRT1+/- mice express approximately 60% of ApoE-
/- SIRT1+/+ protein levels in aortic lysates. n=9 per genotype. (D-F) Quantification of collagen 
content (D), necrotic core size (E), and cap thickness in plaques from aortic sinus. n=8 per 
genotype. (F) TUNEL staining revealed no difference in amount of apoptotic cells. n=6 per 
genotype. 
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Supplemental Figure 2. Diet schemes. (A) 8 weeks after birth, ApoE
-/-
 SIRT1
+/+
 and  
ApoE
-/-
 SIRT1
+/-
 mice were kept on a high-cholesterol diet for 12 weeks. 20-week-old male 
animals were euthanized for tissue harvesting. (B) Bone-marrow from 8-week-old donor mice 
(ApoE
-/-
 SIRT1
+/-
 and ApoE
-/-
 SIRT1
+/+
) was extracted, and 10
6
 bone-marrow cells were 
injected intravenous into irradiated recipient ApoE
-/-
 mice. Transplanted mice were allowed to 
recover for 5 weeks, and were then fed a high-cholesterol diet for 11 weeks prior to tissue 
harvesting. 
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Supplemental Figure 3. SIRT1 staining in aortic plaque of wild-type (healthy) and ApoE-/- 
(diseased) mice. (A) Aortic expression of SIRT1 in wild-type and ApoE
-/-
 mice fed a normal 
or high-cholesterol (HC) diet. Large plaques are only observed in ApoE
-/-
 mice fed a HC diet. 
Isotype controls were exposed longer and show only unspecific staining of the connective 
tissue. Bar = 25 μm. AL: Arterial lumen. (B) SIRT1 colocalizes with endothelial cells (CD31; 
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arrows), and with macrophages (CD68; arrows) in atherosclerotic plaques. EC: endothelial 
cell layer; P: Plaque; VSMC: Vascular smooth muscle cells; AL: Arterial lumen. 
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Supplemental Figure 4. No difference between ApoE-/- SIRT1+/+ (white columns) and ApoE-/- 
SIRT1+/- (black columns) mice regarding glucose plasma levels, body weight, and weight of 
epididymal fat pad. (A) Plasma glucose levels in fed and fasted animals. (B) Plasma insulin 
levels in fed and fasted animals. (C) Total body weight of mice prior to harvesting. (D) 
Percent epididymal fat, given as the percentage of the epididymal fat per total body weight. 
n≥10 per genotype. 
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Supplemental Figure 5. No alterations of plasma lipid distribution in ApoE
-/-
 SIRT1
+/+
 & 
ApoE
-/-
 SIRT1
+/-
 mice. (A, B) Distribution of cholesterol and triglycerides in the plasma of 
ApoE
-/-
 SIRT1
+/+
 mice (■, n = 10 (pooled)) or ApoE-/- SIRT1+/- mice (�, n = 15 (pooled)). No 
differences in the distribution of cholesterol or triglycerides are observed between ApoE
-/-
 
SIRT1
+/+
 & ApoE
-/-
 SIRT1
+/-
 mice. VLDL, very low-density lipoprotein; IDL, intermediate-
density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein. 
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Supplemental Figure 6. Epididymal white adipose tissue expression of Adiponectin 
(Adipoq), Leptin, Visfatin (Nampt), Chemerin (Rarres2), Resistin (Retn) and Plasminogen 
activator inhibitor 1 (PAI-1 or Serpine1) in ApoE-/- SIRT1+/+ (white columns) and ApoE-/- 
SIRT1+/- (black columns) mice. n=6 per genotype.  
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Supplemental Figure 7. SIRT1 inhibition with splitomicin (splito) shows a trend towards 
increased accumulation of oxLDL in RAW 264.7 cells compared to non-treated cells.  
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Supplemental Figure 8. Blood and spleen analysis of bone-marrow transplanted mice. 
Percental FACS analyses of (A) CD4
+
 cells, (B) CD44
+
 population of CD4
+
 cells, (C) 
MHCII
+
 cells, (D) CD8
+
 cells, (E) CD44
+
 population of CD8
+
 cells, (F) B cells, (G) CD11b
+
 
cells, (H) CD11c
+
 cells, (I) F4/80
+
 cells. n=3/transplanted genotype. *p<0.05; **p< 0.01. 
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Supplemental Figure 9. SIRT1 does not affect the expression of SR-A, CD36, or SR-B. 
Aortic RNA levels of SR-A (A) and CD36 (B). (C) SR-A and SR-B immunofluorescence in 
RAW 264.7 macrophages reveals no difference upon splitomicin (Splito) treatment compared 
with non-treated cells (nt). 
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Supplemental Figure 10. Aortic expression of MMP13, MMP3, MMP8, MMP9, MMP14, 
and TIMP3 in ApoE-/- SIRT1+/+ (white columns) and ApoE-/- SIRT1+/- (black columns) mice. 
n=10 per genotype.  
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Supplemental Figure 11. SIRT1 does not affect cholesterol efflux in macrophages. (A) 
Aortic RNA levels of ABCA1. n=6 per genotype. (B) Expression of ABCA1 and ABCG1 in 
ApoE
-/-
 SIRT1
+/+
 (white columns) and ApoE
-/-
 SIRT1
+/-
 (black columns) peritoneal 
macrophages. n=4 per genotype. (C) ApoA-1-dependent cholesterol efflux in RAW 264.7 
macrophages is not affected by 100 μM splitomicin (Splito) compared with untreated control 
groups (nt). 9 cis-retinoic acid (RA) + 22-hydroxycholesterol (22-HC)-stimulation is done to 
analyze LXR/RXR-dependent efflux, cAMP-stimulation to study LXR/RXR-independent 
efflux. n=3 per treatment group. (D) Aortic expression of PPARγ. n=6 per genotype. (E, F) 
Aortic RNA levels of PGC-1α (E, n=10 per genotype) and LXRα (F, n=6 per genotype). 
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SUPPLEMENTARY TABLES 
Supplemental Table 1: Plasma lipid profiles of ApoE
-/-
 SIRT1
+/+
 and ApoE
-/-
 SIRT1
+/-
. 
 ApoE
-/-
 SIRT1
+/+
 
(n=10) 
ApoE
-/-
 SIRT1
+/-
 
(n=14) 
Total cholesterol (mmol/l) 45.54 ± 6.15 39.72 ± 2.56 
Triglycerides (mmol/l) 2.12 ± 0.24 2.03 ± 0.18 
Free fatty acids (mmol/l) 0.99 ± 0.13 0.93 ± 0.09 
 
mean ± SEM. 
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Supplemental Table 2: Plasma cytokine values of ApoE
-/-
 SIRT1
+/+
 and ApoE
-/-
 SIRT1
+/-
. 
 ApoE
-/-
 SIRT1
+/+
 
(n=10) 
ApoE
-/-
 SIRT1
+/-
 
(n=15) 
VCAM-1 (ng/ml) 1146 ± 59.7 1266 ± 62.8 
ICAM-1 (ng/ml) 843 ± 51.4 813 ± 31.1 
TGF-β 6431 ± 644.5 6167 ± 332.7 
IFN-γ (pg/ml) 7.27 ± 3.67 16.15 ± 8.26 
IL-6 (pg/ml) 65.36 ± 21.17 127.54 ± 57.67 
IL-10 (pg/ml) 86.40 ± 40.27 189.30 ± 85.90 
mKC 110.44 ± 22.01 138.81 ± 15.64 
 
mean ± SEM. 
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INTRODUCTION 
 
Inflammation plays a key role in the development and 
progression of atherosclerosis. In early stages of the 
disease, endothelial cells get activated by circulating 
proinflammatory molecules such as cytokines (e.g. 
TNFα) or modified lipoproteins (e.g. oxidized LDL). 
Once activated, these cells express chemokines, 
cytokines, and adhesion molecules, which attract and 
recruit inflammatory cells such as macrophages and T 
cells [1, 2]. Hypertension, hypercholesterolemia, 
diabetes, and aging, which may all be associated with 
an excessive production of reactive oxygen species 
(ROS) and oxidant stress,  may contribute to atheroscle- 
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rosis by affecting endothelial function and inducing 
sustained endothelial activation [2-5]. 
 
The NAD-dependent class III histone deacetylase Sir2 
was found to increase lifespan in yeast [6]. Its 
mammalian orthologue SIRT1 senses caloric restriction, 
improves insulin secretion in pancreatic beta cells, and 
reduces accumulation of fatty acids in white adipose 
tissue [7-9]. Various other SIRT1 targets have been 
identified and characterized in recent years, including 
PGC-1α, NF-κB and LXR [10-13]. NF-κB is of special 
interest in endothelial cells, since it drives the expression 
of important adhesion molecules, such as vascular cell 
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Abstract: Excessive production of  reactive oxygen species  (ROS) contributes to progression of atherosclerosis, at  least  in
part  by  causing  endothelial  dysfunction  and  inflammatory  activation.  The  class  III  histone  deacetylase  SIRT1  has  been
implicated in extension of lifespan. In the vasculature, SIRT1 gain‐of‐function using SIRT1 overexpression or activation has
been  shown  to  improve endothelial  function  in mice and  rats  via  stimulation of endothelial nitric oxide  (NO)  synthase
(eNOS). However, the effects of SIRT1  loss‐of‐function on the endothelium  in atherosclerosis remain to be characterized.
Thus, we have  investigated the endothelial effects of decreased endogenous SIRT1  in hypercholesterolemic ApoE‐/‐ mice.
We  observed  no  difference  in  endothelial  relaxation  and  eNOS  (Ser1177)  phosphorylation  between  20‐week  old  male
atherosclerotic ApoE‐/‐  SIRT1+/‐ and ApoE‐/‐  SIRT1+/+ mice. However,  SIRT1 prevented endothelial  superoxide production,
inhibited NF‐κB  signaling,  and diminished  expression of  adhesion molecules.  Treatment of  young hypercholesterolemic
ApoE‐/‐ SIRT1+/‐ mice with lipopolysaccharide to boost NF‐κB signaling led to a more pronounced endothelial expression of
ICAM‐1  and  VCAM‐1  as  compared  to  ApoE‐/‐  SIRT1+/+  mice.  In  conclusion,  endogenous  SIRT1  diminishes  endothelial
activation in ApoE‐/‐ mice, but does not affect endothelium‐dependent vasodilatation. 
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adhesion molecule-1 (VCAM-1) and intercellular 
adhesion molecule-1 (ICAM-1), which recruit blood 
monocytes to atherosclerotic lesions [14-16]. 
 
Endogenous SIRT1 has been shown to decrease 
macrophage foam cell formation and atherogenesis in 
hypercholesterolemic ApoE-/- SIRT1+/- mice [17]. In 
non-atherosclerotic aortae of rats, dominant-negative 
SIRT1 transfection impairs endothelial function via 
eNOS inhibition ex vivo [18], and endothelial 
overexpression of human SIRT1 diminishes athero-
genesis in ApoE-/- mice and improves vascular function 
[19]. In addition, activation of SIRT1 prevents 
hyperglycemia-induced vascular cell senescence in mice 
with diabetes, thereby protecting from vascular 
dysfunction [20]. Nevertheless, the impact of a SIRT1 
haploinsufficiency on endothelium-dependent vaso-
motion and endothelial cell activation in atherosclerotic 
mice remains to be determined. 
 
In the present study, we therefore investigated the 
effects of a single SIRT1 allele on aortic relaxation and 
endothelial activation in 20-week-old atherosclerotic 
ApoE-/- SIRT1+/+ and ApoE-/- SIRT1+/- mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
Endogenous SIRT1 does not alter endothelial 
function in ApoE-/- mice 
 
Overexpression of human SIRT1 in mouse endothelial 
cells has been shown to diminish atherogenesis in 
ApoE-/- mice. [19] However, the underlying mecha-
nisms remain to be further characterized. To investigate 
the effect of endogenous SIRT1 on endothelium-
dependent vasodilatation and endothelial inflammatory 
activation, we assessed endothelium-dependent function 
and inflammatory pathways in aortic rings from 20-
week-old atherosclerotic ApoE-/- SIRT1+/+ or ApoE-/- 
SIRT1+/- mice. Interestingly, the acetylcholine-mediated 
relaxation of aortic rings after precontraction with 
norepinephrine did not differ between ApoE-/- SIRT1+/+ 
and the haploinsufficient ApoE-/- SIRT1+/- mice (Figure 
1A). Vasoconstriction with norepinephrine and 
endothelium-independent vasodilatation with sodium 
nitroprusside were normal (Figure 1B, C). eNOS-
derived NO plays an important role in vascular 
relaxation, and eNOS activity is mainly regulated by 
Akt-dependent Ser1177 phosphorylation [21].  We observ- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. ApoE‐/‐ SIRT1+/‐ mice do not exhibit endothelial dysfunction. (A) No difference  in relaxation of
aortic  rings  preconstricted  with  norepinephrine  to  the  vasodilator  acetylcholine.  %  Relaxation  =  %  of
precontraction to norepinephrine. (B) Relaxation of aortic rings at increasing sodium nitroprusside concentrations
after norepinephrine precontraction. % Relaxation = % of precontraction  to norepinephrine.  (C) Contraction of
aortic rings at increasing norepinephrine concentrations. % Contraction = % of contraction to 80 mM KCl. ApoE‐/‐
SIRT1+/‐  (blue  line)  and ApoE‐/‐  SIRT1+/+  (black  line).  (D) Aortic protein  levels of  total eNOS  and phospho‐eNOS
(Ser1177). ApoE‐/‐ SIRT1+/‐ (+/‐ and black columns) and ApoE‐/‐ SIRT1+/+ (+/+ and white columns). n=6 per genotype
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ed no difference in the Ser1177 phosphorylation status 
(Figure 1D). Our data indicate that endogenous SIRT1 
in atherosclerotic ApoE-/- mice does not affect 
endothelial function. 
 
Silencing of SIRT1 enhances production of 
endothelial superoxide 
 
Common risk factors predisposing to atherosclerosis, 
such as hypercholesterolemia or aging, are associated 
with oxidant stress at least in part due to an increased 
production of ROS [22]. We measured ROS production 
in human aortic endothelial cells (HAECs) treated with 
either scrambled- or SIRT1-siRNA. SIRT1 silencing 
elevated endothelial ROS levels upon TNFα 
stimulation, whereas under basal conditions there was 
no effect of SIRT1 silencing was observed (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enhanced expression of adhesion molecules in ApoE-
/- SIRT1+/- plaques 
 
Accumulating evidence suggests that chronic 
production of ROS may favor atherogenesis by 
inducing sustained endothelial inflammatory activation 
[2, 5]. Expression of endothelial adhesion molecules 
play an important role in atherogenesis by promoting 
monocyte-derived macrophage recruitment and 
accumulation in the arterial intima [16]. Interestingly, 
expression of ICAM-1 and VCAM-1 was increased in 
atherosclerotic plaques of ApoE-/- SIRT1+/- compared 
with ApoE-/- SIRT1+/+ mice (Figure 3). These findings 
show that SIRT1 prevents adhesion molecule 
expression, an important step in endothelial cell 
activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SIRT1 regulates the expression of endothelial 
adhesion molecules via suppression of NF-κB 
signaling in vitro 
 
NF-κB plays a central role in inflammatory processes 
and its signaling pathway is inhibited by SIRT1 via 
deacetylation [12, 23]. NF-κB induces expression of 
adhesion molecules and inflammatory cytokines, and 
endothelial-specific inhibition of the NF-κB pathway 
protects mice from atherosclerosis [24]. SIRT1 has been 
shown to deacetylate the lysine residue K310 of 
RelA/p65 in human epithelial lung cells [12]. To test 
whether RelA/p65 signaling is suppressed by SIRT1 in 
HAECs, we quantified DNA-bound RelA/p65 in TNFα-
stimulated and unstimulated cells pretreated with the 
SIRT1 inhibitor splitomicin [25]. Binding of RelA/p65 
to naked DNA was enhanced upon treatment with the 
SIRT1 inhibitor splitomicin after TNFα stimulation 
(Figure 4A). To evaluate, if SIRT1 is also deacetylating 
K310 of RelA/p65 in HAECs, as previously reported 
Figure 2.  Superoxide production  is  increased  in HAECs after
SIRT1‐siRNA  compared  with  scrambled‐siRNA‐treatment  1  h
after TNFα stimulation. n=2. ***p<0.001. 
 
Figure  3.  SIRT1 deletion  increases  adhesion  molecule
expression. ICAM‐1 and VCAM‐1 staining and quantification  in
plaques  from  aortic  sinus. Magnifications: X40. ApoE‐/‐  SIRT1+/+
(+/+,  n=6, white  columns)  and  ApoE‐/‐  SIRT1+/‐  (+/‐,  n=6,  black
columns). *p<0.05. 
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for HEK 293T cells [12], we stimulated SIRT1- or 
scrambled-siRNA-treated HAECs with TNFα and 
performed p65 immunoprecipitations. K310-p65 was 
increased in SIRT1-siRNA-treated HAECs (Figure 4B). 
To further test if suppression of NF-κB signaling also 
affects the expression of adhesion molecules, we 
analyzed the expression of VCAM-1, a known NF-κB 
signaling target, in more detail. SIRT1-siRNA treatment 
enhanced expression of VCAM-1 in HAECs upon 
TNFα stimulation (Figure 4C).  
 
SIRT1 regulates the expression of inflammatory 
endothelial molecules in vivo 
 
Since SIRT1 suppresses NF-κB signaling in HAECs, 
we investigated whether the same concept holds true in 
mouse aortae. Binding of RelA/p65 to naked DNA was 
higher in nuclear extracts of ApoE-/- SIRT1+/- than 
ApoE-/- SIRT1+/+ mice (Figure 5A). Importantly, aortic  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
expression of other inflammatory molecules, namely IL-
1β, TNFα, and P-Selectin (P-Sel), was also enhanced in 
ApoE-/- SIRT1+/- compared to ApoE-/- SIRT1+/+ mice 
(Figure 5B). The expression of these inflammatory 
genes is regulated by NF-κB. Lipopolysaccharides 
(LPS) induce strong activation of NF-κB signaling and 
the expression of target genes [26]. To address the in 
vivo relevance of the NF-κB suppression by SIRT1, we 
examined the expression of two known NF-κB-
dependent genes, ICAM-1 and VCAM-1, in aortae from 
young 8-week-old ApoE-/- SIRT1+/- and ApoE-/- SIRT1+/+ 
mice without atherosclerosis in descending thoracic 
aortae 3 hours after intraperitoneal injection of LPS. LPS 
induced an upregulation of both ICAM-1 and VCAM-1 
in intimal endothelial cells of aortae from ApoE-/- 
SIRT1+/- compared with ApoE-/- SIRT1+/+ mice (Figure 
5C, D). These findings indicate that endogenous SIRT1 
is sufficient to prevent adhesion molecule expression in 
both human and mouse activated endothelial cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. SIRT1 suppresses NF‐κB signaling  in HAECs.  (A) RelA/p65 DNA binding  is higher  in
HAEC  pretreated with  splitomicin  (Splito)  compared with  the  untreated  group  (‐),  30 min  after
TNFα‐stimulation.  n=5.  (B)  RelA/p65  immunoprecipitation  in  HAECs  reveals  more  acetyl‐K310‐
RelA/p65  upon  SIRT1‐siRNA  treatment  20  min  after  TNFα‐stimulation  compared  to  scrambled
siRNA‐treated cells. n=2.  (C) Western blot showing SIRT1 silencing using siRNA  (top), and VCAM‐1
mRNA expression 5 h after TNFα stimulation in SIRT1‐siRNA treated HAECs (graph). n=4. *p<0.05.  
  
www.impactaging.com                      4                                             AGING, June 2010, Vol.2 No.6 
- 60 -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
Enhanced atherogenesis in ApoE-/- SIRT1+/- mice is 
causally linked to increased expression of adhesion 
molecules in aortae. Indeed, we provide in vitro and in 
vivo evidence that underlines this concept by 
demonstrating that ApoE-/- SIRT1+/- mice exhibit 
increased endothelial expression of ICAM-1 and 
VCAM-1 upon LPS injection. Importantly, upregulation 
of these adhesion molecules promotes recruitment of 
monocytes and T cells to luminal endothelial cells [27]. 
In concert with increased levels of IL-1β, TNFα, and P-
Sel in the activated arterial wall, these molecular events 
are sufficient to recruit circulating leukocytes to  athero- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
sclerotic lesions, especially monocyte-derived 
macrophages and T cells. 
 
At the molecular level, the inhibitory effects of SIRT1 
on adhesion molecule expression may be mediated via 
RelA/p65 signaling. Our data show that SIRT1 
suppresses binding of RelA/p65 to naked DNA, 
therefore interfering with a crucial step in the 
transcriptional activation of NF-κB. These findings are 
in line with previous reports showing that SIRT1 
deacetylases RelA/p65 at the lysine residue K310 in 
human epithelial lung cells [12]. In agreement with 
these reports, we demonstrate that this mechanism of 
RelA/p65 signaling suppression is present in HAECs.  
 
Figure 5.  SIRT1 prevents  expression of  endothelial  adhesion molecules.  (A)  RelA/p65 DNA‐
binding  in  aortic nuclear  extracts  from ApoE‐/‐  SIRT1+/‐  (+/‐, n=8, black  column)  is  elevated  in ApoE‐/‐
SIRT1+/+  (+/+,  n=6, white  column) mice.  (B)  Expression  levels  of  IL‐1β,  P‐Selectin,  and  TNFα  in  aortic
lysates of ApoE‐/‐ SIRT1+/+ (white columns) and ApoE‐/‐ SIRT1+/‐ (black columns) mice. n=8 per genotype.
Enhanced expression of  ICAM‐1 (C) and VCAM‐1 (D)  is observed  in non‐atherosclerotic ApoE‐/‐ SIRT1+/‐
(+/‐ and black columns) compared with ApoE‐/‐ SIRT1+/+ (+/+ and white columns) aortae 3 h post intra‐
peritoneal LPS (striped columns) injection. n=6 per genotype. Scale: 50 μm. *p<0.05; **p< 0.01. 
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Surprisingly, we observe no endothelial dysfunction in 
ApoE-/- SIRT1+/- mice. In contrast, Pearson et al. showed 
improved endothelial function in mice kept on a diet 
with a very high resveratrol content (2400 mg/kg/food) 
that could be mediated by SIRT1 activation [28]. 
However, such effects may also be related to activation 
of AMPK by resveratrol or via other targets of this 
compound [29, 30]. Furthermore, adenovirus-mediated 
inhibition of endothelial SIRT1 diminishes 
endothelium-dependent vasodilatation in rat aortic rings 
and decreases bioavailable NO levels [18]. Others 
reported improved relaxation in ApoE-/- mice with 
endothelial SIRT1 overexpression that were kept on a 
high-fat diet [19]. However, in this study WT aortic 
rings showed also marked endothelial dysfunction by 
relaxing only up to 50%, thereby casting doubts on the 
endothelial integrity of the preparations [19]. In 
contrast, we observed no change in endothelial 
function or aortic eNOS activity between hyper-
cholesterolemic ApoE-/- SIRT1+/- and ApoE-/- SIRT1+/+ 
mice, suggesting that the endothelial-protective effects 
of SIRT1 include factors other than eNOS-dependent 
NO production. Indeed, we detected a profound 
increase in ROS-production after silencing of SIRT1 
in TNFalpha-stimulated endothelial cells, indicating 
that endogenous SIRT1 inhibits agonist-induced ROS 
production in endothelial cells. Of note, an excessive 
production of ROS has been implicated in endothelial 
inflammatory activation and the pathogenesis of 
atherosclerosis [31]. Therefore, inhibition of excessive 
endothelial ROS production likely represents an 
important endothelial-protective action of endogenous 
SIRT1. 
 
Taken together, our results show that SIRT1 does not 
influence endothelium-dependent vascular function in 
ApoE-/- mice, but it prevents superoxide production in 
endothelial cells and reduces the expression of 
inflammatory adhesion molecules by suppressing NF-
κB signaling. Although the specificity of available 
SIRT1 activators has been questioned recently [32], it is 
likely that SIRT1 activators may prevent atherosclerosis 
and other inflammatory diseases by hindering pro-
oxidative and inflammatory processes. 
 
MATERIALS AND METHODS 
 
Animals. ApoE-/- SIRT1+/- and ApoE-/- SIRT1+/+ mice 
were described previously [17]. Male mice were fed a 
high-cholesterol diet (1.25% total cholesterol, Research 
Diets) for 12 weeks starting at the age of 8 weeks. All 
animal procedures were approved by the local animal 
committee and performed in accordance with our 
institutional guidelines. 
Cell culture. Human aortic endothelial cells (HAEC, 
Cambrex Bio Science) were treated with 100 μM 
splitomicin (Sigma-Aldrich) to perform analysis of NF-
κB binding to DNA. HAEC were stimulated for 30 
minutes with 10 ng/ml human TNFα (R&D Systems). 
 
siRNA transfection. Transient transfection siRNA into 
HAEC were done with lipofectamin lipofectamin RNAi 
MAX (Invitrogen). The oligos used for SIRT1-siRNA 
have been described previously [9]. 
 
Immunohistochemistry and immunofluorescence. Serial 
cryosections from the aortic sinus were stained with 
rabbit anti-von Willebrand Factor (Dako), rat anti-
CD31, rat anti-VCAM-1 (BD Biosciences), rat anti-
ICAM-1 (Serotec). Fluorescence was analyzed on a 
Leica TCS SP2 confocal microscope and means were 
taken from n=6 different mice evaluating 6 serial 
cryosections/tissue from each mouse. 
 
RNA and protein analysis. Total RNA isolated from 
proximal aortae and HAEC was extracted with TRIZOL 
(Invitrogen), reverse transcribed, and the cDNA 
quantified by SYBR green qPCR using specific primers. 
For protein analysis, aortic tissue lysates were blotted 
and incubated with rabbit anti-SIRT1, rabbit anti-eNOS 
(Santa Cruz Biotechnology), and rabbit anti-Phospho-
eNOS (Ser1177) (Cell Signaling Technology). 
 
Endothelial function. Aortic rings (2–3 mm long) were 
connected to an isometric force transducer 
(MultiMyograph), suspended in a 95% O2/5% CO2 
aerated organ chamber filled with KREBS buffer (118 
mM NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 1.2 mM 
NaH2PO4, 1.2 mM Na2SO4, 2.5 mM CaCl2, 25 mM 
NaHCO3, 10 mM glucose, pH to 7.4). Concentration-
dependent contractions were established by using 
norepinephrine (10−9 to 10−4 mol/liter; Sigma–Aldrich).  
Concentration–response curves were obtained in a 
cumulative fashion. 8 rings cut from the same artery 
were studied in parallel. Responses to acetylcholine 
(10−9 to 10−6 mol/liter; Sigma–Aldrich) were obtained 
during submaximal contraction to norepinephrine. The 
NO donor sodium nitroprusside (10−10 to 10−5 mol/liter; 
Sigma–Aldrich) was added to test endothelium-
independent relaxations. 
 
LPS assay. 6 8-week-old ApoE-/- SIRT1+/- and ApoE-/- 
SIRT1+/+ mice kept on standard diet were used for this 
assay. At this age and under normal diet, ApoE-/- mice 
do not exhibit plaques in their thoraco-abdominal 
aortae. Mice were injected i.p. with 100 μg of LPS 
(Sigma) in PBS, sacrificed 3 hours post injection and 
thoraco-abdominal aortae embedded in OCT. 
Cryosections (5 μm) were cut and stained for ICAM-1 
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or VCAM-1. Relative expression is given as the ratio of 
ICAM-1 or VCAM-1 staining area to von Willebrand 
Factor (vWF) staining area, respectively. Quantification 
of fluorescence was done with analySIS (Olympus) on 
microscopic images using identical exposure settings. 
 
Quantification of DNA-bound RelA/p65. HAEC were 
pretreated with splitomicin for one hour and stimulated 
with 10 ng/ml TNFα for 30 minutes. Nuclear extracts of 
aortic tissue samples were obtained with the Nuclear 
Extract kit (ActiveMotif) using a Dounce pestle, and a 
RelA/p65 transcription factor assay was performed 
using the TransAM kit (ActiveMotif) according to the 
manufacturer’s instructions.  
 
Immunoprecipitation. HAEC were treated with 50 μM 
SIRT1 or scrambled siRNA over night, followed by 10 
ng/ml TNFα stimulation for 20 minutes. Cells were then 
harvested and protein extracted in lysis buffer (20 mM 
HEPES, pH 7.5, 80 mM NaCl, 2.5 mM MgCl2, 1 mM 
EDTA, 100 μM Splitomicin, 0.5% NP-40, 1 mM PMFS 
(phenylmethylsulfonyl fluoride), 10 µg/ml aprotinin, 
and 10 μg/ml leupeptin). 1 mg whole-cell lysates were 
immunoprecipitated with rabbit anti-p65 (Santa Cruz) 
using Protein G agarose (Millipore). Immuno-
precipitated samples were immunoblotted with rabbit 
anti-acK310-p65 (Abcam), and the total lysates (5% 
input) with rabbit anti-SIRT1 and rabbit anti-p65. 
 
Detection of endothelial cell superoxide production by 
electron spin resonance spectroscopy. The effect of 
SIRT1 on endothelial cell superoxide production was 
assessed in unstimulated and TNFα-stimulated (10 
ng/ml) HAEC by ESR spectroscopy using the spin 
probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetra-
methylpyrrolidine (CMH; Noxygen). HAEC were 
incubated with 50 nM scrambled or SIRT1-siRNA with 
or without TNFα for one hour and resuspended in 
Krebs-Hepes buffer (pH 7.4; Noxygen) containing 
diethyldithiocarbamic acid sodium salt (5 μM, 
Noxygen) and deferoxamine methanesulfonate salt (25 
μM, Noxygen). ESR spectra were recorded after 
addition of CMH (final concentration 200 μM) under 
stable temperature conditions using a Bruker e-scan 
spectrometer (Bruker Biospin). The ESR instrumental 
settings were as follows: center field, 3495 G; field 
sweep width, 10.000 G; microwave frequency, 9.75 
GHz; microwave power, 19.91 mW; magnetic field 
modulation frequency, 86.00 kHz; modulation 
amplitude, 2.60 G; conversion time, 10.24 msec; 
detector time constant, 328 msec; nuber of x-scans, 10. 
 
Statistical analyses. Data are presented as mean ± SEM. 
Statistical significance of differences was calculated 
using an ANOVA with post hoc Tukey’s test or Student’s 
unpaired t test. Significance was accepted at p<0.05. 
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Aims The mammalian silent information regulator-two 1 (Sirt1) blunts the noxious effects of cardiovascular risk factors
such as type 2 diabetes mellitus and obesity. Nevertheless, the role of Sirt1 in regulating the expression of tissue
factor (TF), the key trigger of coagulation, and arterial thrombus formation remains unknown.
Methods
and results
Human as well as mouse cell lines were used for in vitro experiments, and C57Bl/6 mice for in vivo procedures. Sirt1
inhibition by splitomicin or sirtinol enhanced cytokine-induced endothelial TF protein expression as well as surface
activity, while TF pathway inhibitor protein expression did not change. Sirt1 inhibition further enhanced TF mRNA
expression, TF promoter activity, and nuclear translocation as well as DNA binding of the p65 subunit of nuclear
factor-kappa B (NFkB/p65). Sirt1 siRNA enhanced TF protein and mRNA expression, and this effect was reduced
in NFkB/p652/2 mouse embryonic fibroblasts reconstituted with non-acetylatable Lys310-mutant NFkB/p65. Acti-
vation of the mitogen-activated protein kinases p38, c-Jun NH2-terminal kinase, and p44/42 (ERK) remained unaf-
fected. In vivo, mice treated with the Sirt1 inhibitor splitomicin exhibited enhanced TF activity in the arterial vessel
wall and accelerated carotid artery thrombus formation in a photochemical injury model.
Conclusion We provide pharmacological and genetic evidence that Sirt1 inhibition enhances TF expression and activity by
increasing NFkB/p65 activation in human endothelial cells. Furthermore, Sirt1 inhibition induces arterial thrombus
formation in vivo. Hence, modulation of Sirt1 may offer novel therapeutic options for targeting thrombosis.
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1. Introduction
Cardiovascular diseases represent a major health burden. Acute vas-
cular events such as myocardial infarction and ischaemic stroke
account for the majority of deaths in Western countries.1 Formation
of an arterial thrombus is the central event in such acute vascular syn-
dromes. Tissue factor (TF) is the key trigger of the coagulation
cascade and thereby crucially involved in arterial thrombosis.2 –4 Its
impact on thrombus formation may be enhanced in atherosclerosis
since TF expression is induced in the inflammatory environment of
atherosclerotic plaques.5 In line with this notion, clinical studies
demonstrate higher TF levels in the culprit lesion of patients with
acute coronary syndromes.6 Numerous inflammatory mediators
such as tumour necrosis factor alpha (TNF-a7) or histamine,8 but
also pro-thrombotic mediators like thrombin,9 induce endothelial
TF expression by activating the MAP kinases p38, ERK, and c-Jun
NH2-terminal kinase (JNK), and consequently transcription factors
such as nuclear factor-kappa B (NFkB).2
Silent information regulator-two (Sir2) is an NAD+-dependent
class III histone deacetylase.10 The mammalian sirtuins are evolutiona-
rily conserved homologues of the yeast Sir2,11 and silent information
regulator-two 1 (Sirt1) is the closest orthologue.12 In addition to
maintaining chromatin structure,10 Sirt1 has been shown to regulate
transcription factors such as forkhead box class O (FOXO),13
† These authors contributed equally to this work.
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p53,14 peroxisome proliferator-activated receptor-g,15 endothelial
nitric oxide synthase (eNOS),16 and p65 subunit of nuclear factor-
kappa B (NFkB/p65).17 Hence, Sirt1 is critically involved in cellular
responses to stress,18 senescence,19 and mitochondrial function.20
Furthermore, endothelial overexpression of Sirt1 diminishes plaque
formation in a mouse model of atherosclerosis,21 and pharmacological
activation of Sirt1 improves glucose homeostasis in mice and
humans.22 Based on these findings, Sirt1 modulators are under inves-
tigation in clinical trials for the treatment of patients with cardiovascu-
lar risk factors.
Since downstream targets of Sirt1 such as NFkB are involved in the
regulation of TF expression, this study was designed to investigate the
effect of Sirt1 on TF expression and arterial thrombus formation.
2. Methods
2.1 Cell culture
Human aortic endothelial cells (HAECs; Clonetics, Allschwil, Switzerland)
were cultured as described.23 Briefly, adhering HAECs were grown to con-
fluence and rendered quiescent for 24 h in medium containing 0.5% FCS
before stimulation. Sirt12/2 mouse embryonic fibroblasts (MEFs) were
kindly provided by David Sinclair (Harvard Medical School, Boston, MA,
USA) and were grown to confluence in Dulbecco’s modified Eagle’s
medium supplemented with 10% FCS. Similarly, NFkB/p652/2 MEFs with
reconstituted wild-type NFkB/p65 or non-acetylatable Lys310-mutant
NFkB/p65 were used as described previously.24 Cells were pre-treated
with splitomicin (Sigma, Buchs, Switzerland), sirtinol (Calbiochem,
Lucerne, Switzerland), or resveratrol (Sigma) for 1 h before stimulation
with 5 or 10 ng/mL TNF-a (R&D Systems, Minneapolis, MN, USA), 1 U/
mL thrombin (R&D Systems), or 1025 mol/L histamine (Sigma), respect-
ively. Transient transfection with pcDNA3.1-SIRT1 or Sirt1 siRNA (Sirt1
siRNA oligonucleotide sequence: 5′-GATGAAGTTGACCTCCTCA-3′)
was performed using Lipofectamine Reagent (Invitrogen, Basel, Switzer-
land) or Lipofectamine RNAi MAX (Invitrogen), respectively, as described
previously.15,25 Cytotoxicity was assessed by a colorimetric assay to detect
lactate dehydrogenase (LDH; Roche, Basel, Switzerland).
2.2 Western blot analysis
Protein expression was determined as described.8 Antibodies against
human TF, tissue factor pathway inhibitor (TFPI; both from American
Diagnostica, Stamford, CT, USA), and Sirt1 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) were used at 1:2000 dilution. Antibodies against
phosphorylated p38 mitogen-activated protein (MAP) kinase (p38), p44/
42 MAP kinase (ERK), and JNK (all from Cell Signaling, Danvers, MA,
USA) were used at 1:1000, 1:5000, and 1:1000 dilution, respectively. Anti-
bodies against total p38, ERK, and JNK (all from Cell Signaling) were
diluted to 1:3000, 1:10 000, and 1:1000, respectively. The antibody
against IkB-a (Santa Cruz Biotechnology) was applied at a 1:1000 dilution.
Alpha-tubulin (Sigma) were applied to control protein loading (1:10 000
dilution). Primary antibodies were detected with a horseradish
peroxidase-linked secondary antibody (Amersham, Munich, Germany).
2.3 Real-time PCR
Total RNA was extracted from HAECs with 1 mL TRIzol Reagent (Invi-
trogen) as described.23 Conversion of total cellular RNA to cDNA was
carried out with Moloney murine leukaemia virus reverse transcriptase
and random hexamer primers (Amersham) in a final volume of 33 mL
using 4 mg of RNA. The total cDNA pool obtained served as template
for subsequent PCR amplification with primers specific for full-length
TF (sense primer: 5′-TCCCCAGAGTTCACACCTTACC-3′ , antisense
primer: 5′-CCTTTCTCCTGGCCCATACAC-3′; bases 508–529 of F3
cDNA; NCBI no. NM 001993). Real-time PCR amplification was
performed in an MX3000P PCR cycler (Stratagene) using the SYBR
Green JumpStart kit (Sigma) in 25 mL final reaction volume containing
2 mL cDNA, 10 pmol of each primer, 0.25 mL of internal reference dye,
and 12.5 mL of JumpStart Taq ReadyMix (buffer, dNTP, stabilizers, SYBR
Green, Taq polymerase, and JumpStart Taq antibody). A melting curve
analysis was performed after amplification to verify the accuracy of the
amplicon. Ribosomal L28 RNA in HAECs or S12 RNA in MEFs served
as loading control.
2.4 TF activity in vitro
TF surface activity in HAECs was analysed using a colorimetric assay
(American Diagnostica). Cells were incubated at 378C with human FVIIa
and FX, allowing for the formation of the TF/FVIIa complex at the cell
surface. Conversion of FX to FXa was measured by the ability of FXa
to cleave a chromogenic substrate. A standard curve was established
with lipidated human TF to assure that the results were in the linear
range of detection.
2.5 Histone deacetylase activity
Cell-based histone deacetylase activity (HDAC) assay was performed
according to the manufacturer’s instructions (BIOMOL, Hamburg,
Germany). Briefly, HAECs were starved in phenol-red-free media contain-
ing 0.5% FCS. After 24 h, cells were incubated with 200 mmol/L Fluor de
Lys substrate with or without trichostatin A (TSA; 1 mmol/L, BIOMOL),
and with or without splitomicin (100 mmol/L, Sigma). After 2 h, cells
were incubated with Fluor de Lys developer, lysed after 30 min, and
equal amount of lysates were analysed for enzyme activity using a fluor-
escence reader (Ex. 360 nm, Em. 460 nm).
2.6 TF promoter activity
An adenoviral vector (Ad5/hTF/Luc) containing the minimal TF promoter
(2227 to +121 bp) upstream of the Luciferase cDNA and the SV40
PolyA signal was prepared as described.26 For viral transfection, the
vector was added to HAEC at 100 pfu/cell for 1 h. HAEC were kept in
growth medium for 24 h and then serum-starved for 24 h prior to
TNF-a stimulation with or without Sirt1 inhibitor pre-treatment. Cells
were stimulated with TNF-a for 30 min. Firefly luciferase activity was
determined in cell lysates using a luminometer (Bertholg Technologies,
Bad Wildbad, Germany).
2.7 NFkB DNA binding assay and NFkB/p65
immunofluorescence
Adhering HAECs were pre-treated with Sirt1 inhibitors for 1 h, followed
by stimulation with 10 ng/mL TNF-a for additional 30 min. Nuclear
protein was obtained by using a nuclear extraction kit (Active Motif, Rix-
ensart, Belgium). Cells were harvested in hypotonic buffer for 15 min
before centrifugation, isolated nuclei were resuspended in a hypertonic
buffer, and nuclear protein was extracted by incubation on a rotator
for 30 min. The supernatant containing the nuclear protein was collected
after centrifugation. The DNA binding reaction was carried out with 5 mg
of nuclear protein in a 96-well plate coated with consensus sequences for
NFkB (GGGACTTTCC) for 1 h at room temperature. After washing,
NFkB/p65 antibody (Active Motif) was added and incubated for 1 h, fol-
lowed by incubation with a horseradish peroxidase-conjugated secondary
antibody. Finally, NFkB/p65 DNA binding was assessed spectrophotome-
trically at 450 nm.
HAECs were stained with FITC-labelled mouse anti-NFkB/p65 (Santa
Cruz Biotechnology). Cytoplasmic NFkB/p65 was analysed using an SP2
confocal microscope (Leica), and quantification performed with the open-
source software CellProfiler.27 Intensity of the green channel was
measured in the cytoplasm (nuclear area subtracted from the total cell
area) of at least 150 cells per treatment group at the Z-section where
the nuclei had their largest diameter.
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2.8 NFkB/p65 immunoprecipitation
HAECs were treated with 50 mM SIRT1 or scrambled siRNA overnight,
followed by stimulation with TNF-a (10 ng/mL) for 20 min. Cells were
then harvested and protein extracted in lysis buffer (20 mM HEPES, pH
7.5, 80 mM NaCl, 2.5 mM MgCl2, 1 mM EDTA, 0.5% NP-40, 1 mM phenyl-
methylsulfonyl fluoride, 10 mg/mL aprotinin, 10 mg/mL leupeptin, and
100 mM splitomicin). One milligram whole-cell lysates were immunopre-
cipitated with rabbit anti-NFkB/p65 (Santa Cruz) using Protein G agarose
(Millipore, Zug, Switzerland). Immunoprecipitated samples were immuno-
blotted with rabbit anti-acLys310 NFkB/p65 (Abcam, Cambridge, UK), the
total lysates (5% input) with rabbit anti-SIRT1 and rabbit anti-NFkB/p65
(both from Santa Cruz Biotechnology).
2.9 Carotid artery thrombosis model and TF
activity in vivo
The investigation conforms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publication
no. 85-23, revised 1996). All animal procedures were approved by the
local animal committee (Kantonales Veterina¨ramt Zurich, Switzerland)
and performed in accordance with our institutional guidelines. C57BL/6
mice aged 12–14 weeks weighing on average 27 g were anaesthetized
by intraperitoneal injection of 87 mg/kg sodium pentobarbital (Butler,
Columbus, OH, USA). Rose Bengal (Fisher Scientific, Fair Lawn, NJ,
USA) was diluted to 12 mg/mL in phosphate-buffered saline and then
injected into the tail vein at a concentration of 63 mg/kg. Mice were
secured in a supine position, placed under a dissecting microscope, and
the right common carotid artery was exposed following a midline cervical
incision. A Doppler flow probe (Model 0.5 VB, Transonic Systems, Ithaca,
NY, USA) was applied and connected to a flowmeter (Transonic, Model
T106). Six minutes after Rose Bengal injection, a 1.5 mW green light
laser (540 nm; Melles Griot, Carlsbad, CA, USA) was applied to the site
of injury at a distance of 6 cm for 60 min or until thrombosis occurred.
From the onset of injury, blood flow was monitored up to 120 min, at
which time the experiment was terminated.7 Occlusion was defined as
flow ≤0.1 mL/min for at least 1 min. Mice were divided into two
groups: splitomicin (80 mg/kg with an intraperitoneal injection every
24 h for 5 days), or vehicle control (0.5% methylcellulose).
Right carotid arteries were homogenized in 50 mL of lysis buffer and left
to stand on ice for 30 min. TF activity was measured by using the colori-
metric assay as described above.
2.10 Statistical analysis
Data are indicated as mean+ SEM. Unpaired Student’s t-test was used to
evaluate differences between two groups. For statistical analysis of data
from multiple groups, one-way ANOVA was performed. A P value
,0.05 denoted a significant difference. All statistical values are additionally
summarized in the Supplementary material online, Table S1.
3. Results
3.1 Sirt1 inhibition enhances TF expression
and activity
TF protein expression was determined in TNF-a (5 ng/mL for 5 h)
stimulated HAECs in the presence or absence of increasing concen-
trations of splitomicin (25–200 mmol/L) or sirtinol (15–60 mmol/L),
respectively. Both inhibitors enhanced TNF-a-induced TF protein
expression in a concentration-dependent manner; maximal activation
occurred at 100 mmol/L in splitomicin and at 30 mmol/L in sirtinol-
treated cells, respectively (n ¼ 4; P, 0.05; Figure 1A and C ). These
effects were paralleled by an increased TF surface activity in cells pre-
treated with either Sirt1 inhibitor (n ¼ 4; P, 0.01, Figure 1B and D).
Sirt1 knockdown using specific siRNA enhanced TNF-a-induced TF
protein expression (n ¼ 4; P, 0.01; Figure 1E); western blot analysis
confirmed reduced Sirt1 expression in cells transfected with Sirt1
siRNA (n ¼ 4; P, 0.01; Figure 1F). Sirt1 inhibition also enhanced TF
protein expression in response to stimulation with histamine
(1025 mol/L) or thrombin (1 U/mL), respectively (n ¼ 4; P, 0.05;
Figure 2A). The expression of TFPI, the physiological antagonist of
TF, remained unaffected (n ¼ 4; P ¼ NS; Figure 2B). TNF-a did not
alter endogenous Sirt1 protein expression (n ¼ 4; P ¼ NS;
Figure 2C), and no changes in cell morphology nor LDH release
were detected by any of these treatments (n ¼ 4 for each; P ¼ NS;
Supplementary material online, Figure S1).
3.2 TF mRNA expression is induced
by Sirt1 inhibition
Real-time rtPCR revealed that TNF-a (5 ng/mL) induced TF mRNA
expression within 1 h (n ¼ 4; P, 0.05; Figure 3A). Both splitomicin
and sirtinol enhanced TF mRNA expression in stimulated endothelial
cells (splitomicin: n ¼ 4; P, 0.05; Figure 3A, sirtinol: n ¼ 4; P, 0.05;
Figure 3B). In parallel, Sirt1 knockdown using siRNA enhanced
TNF-a-stimulated TF mRNA expression (n ¼ 4; P, 0.01; Figure 3C).
3.3 Sirt1 inhibition reduces HDAC
class III activity
A cell-based HDAC assay was performed in HAECs to confirm that
the Sirt1 inhibitor splitomicin diminishes intracellular deacetylase
activity. Cells were treated with 1 mmol/L TSA to inactivate HDAC
classes I and II in the presence or absence of splitomicin
(100 mmol/L). Consistent with inhibition of HDAC class III, splitomicin
reduced deacetylase activity (n ¼ 4; P, 0.05; Supplementary material
online, Figure S2A) as compared with TSA alone. In contrast, splitomi-
cin did not affect TF protein expression in Sirt12/2 MEFs (n ¼ 4; P ¼
NS; Supplementary material online, Figure S2B).
3.4 Activation of Sirt1 impairs TF
expression and activity
Pharmacological activation of Sirt1 by resveratrol, a commonly used,
but less specific Sirt1 activator, impaired TNF-a-induced TF protein
and mRNA expression (n ¼ 4; P, 0.01 for TF protein, and P,
0.05 for TF mRNA; Supplementary material online, Figure S3A and
B). In parallel, overexpression of Sirt1 in Sirt12/2 MEFs reduced
TNF-a-induced TF expression (n ¼ 4; P, 0.01; Supplementary
material online, Figure S3C and D).
3.5 Sirt1 inhibition enhances TF promoter
activity
To assess whether Sirt1 inhibition enhances TF promoter activity, the
impact of splitomicin and sirtinol on the TF promoter was analysed.
HAECs were transfected with a luciferase plasmid under control of
the human minimal TF promoter (2221 up to +121 bp). Splitomicin
and sirtinol enhanced stimulated TF promoter activity as compared
with TNF-a alone (n ¼ 5; P, 0.01; Figure 4A and B).
3.6 MAP kinase activation is not affected by
Sirt1 inhibition
To assess whether modulation of Sirt1 activity alters MAP kinase acti-
vation, HAECs were examined at different time points after TNF-a
stimulation. The MAP kinases p38, ERK, and JNK were transiently
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Figure 1 Sirt1 inhibition enhances endothelial TF expression and activity. (A and B) Splitomicin enhances TNF-a-induced TF protein expression
(*P, 0.05 vs. TNF-a alone) and surface activity (*P, 0.01 vs. TNF-a alone) in human endothelial cells. (C and D) Sirtinol exerts similar effects
on TF protein expression (*P, 0.05 vs. TNF-a alone) and activity (*P, 0.01 vs. TNF-a alone). (E and F) Sirt1 siRNA enhances TNF-a-induced
TF protein expression (*P, 0.01 vs. TNF-a alone).
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activated by TNF-a (n ¼ 3; Supplementary material online, Figures S4
and S5). Phosphorylation of p38, ERK, and JNK remained unaffected in
cells pre-treated with either splitomicin (n ¼ 3; P ¼ NS; Supplemen-
tary material online, Figure S4) or sirtinol, respectively (n ¼ 3; P ¼
NS; Supplementary material online, Figure S5). Total expression of
MAP kinases remained unchanged at any time point with or
without Sirt1 inhibitors.
3.7 Sirt1 inhibition enhances NFkB/p65
DNA binding via deacetylation of Lys310
of NFkB/p65
NFkB/p65 is a transcription factor that regulates TF expression. Thus,
the effect of Sirt1 inhibition on NFkB/p65 activation was investigated.
TNF-a (10 ng/mL) induced a significant increase in NFkB/p65 DNA
binding as compared with control (n ¼ 5; P, 0.01; Figure 5A and
B). Sirt1 inhibition with splitomicin (100 mmol/L) or sirtinol
(30 mmol/L) enhanced NFkB/p65 DNA binding (n ¼ 5; P, 0.01;
Figure 5A and B). In line with this, translocation of NFkB/p65 from
the cytoplasm to the nucleus was increased after TNF-a stimulation
as confirmed by NFkB/p65 immunofluorescence and pre-treatment
with splitomicin further enhanced NFkB/p65 nuclear translocation
(n ¼ 5; P, 0.01; Supplementary material online, Figure S6).
Since degradation of the inhibitory protein of NFkB, IkB-a, is an
early step in activation of NFkB/p65, the effect of Sirt1 inhibition on
IkB-a degradation was investigated. TNF-a induced a transient degra-
dation of IkB-a (n ¼ 3; Supplementary material online, Figures S4 and
S5). Neither splitomicin nor sirtinol altered the degradation pattern of
IkB-a as compared with TNF-a alone (n ¼ 3; P ¼ NS; Supplementary
material online, Figures S4 and S5).
For further analysis, NFkB/p652/2 MEFs were used and reconsti-
tuted with either wild-type NFkB/p65 or a non-acetylatable Lys310-
mutant NFkB/p65. The effect of Sirt1 siRNA on TF expression was
less pronounced in MEFs reconstituted with the non-acetylatable
Lys310-mutant NFkB/p65 as compared with the wild-type NFkB/p65
(n ¼ 5; P, 0.01; Figure 5C), although both types of reconstituted
cells exhibited enhanced TF mRNA expression after TNF-a stimulation
when Sirt1 was knocked down by siRNA (n ¼ 5; P, 0.05; Figure 5C).
Western blot analysis confirmed reduced Sirt1 expression in all the
cells transfected with Sirt1 siRNA (n ¼ 4; P, 0.05; Figure 5D).
Sirt1 was also silenced in HAECs using siRNA. The cells were
stimulated with TNF-a (10 ng/mL) and a NFkB/p65
Figure 2 Splitomicin induce TF expression in response to different mediators, but does not alter TFPI expression. TNF-a does not alter Sirt1
expression. (A) TNF-a, histamine, and thrombin induce TF protein expression. Splitomicin up-regulates TF expression in response to each stimulus
(*P, 0.05 vs. each stimulation factor). (B) Splitomicin does not alter TFPI expression (P ¼ NS). (C) TNF-a stimulation does not change endogenous
expression of Sirt1 (P ¼ NS).
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immunoprecipitation was performed. There was a higher extent of
Lys310 NFkB/p65 acetylation in cells with impaired Sirt1 expression
(n ¼ 3; Figure 5E).
3.8 Sirt1 inhibition induces TF activity and
arterial thrombosis in vivo
C57Bl/6 mice were treated with splitomicin (80 mg/kg body weight,
intraperitoneal injection every 24 h for 5 days) or vehicle (0.5%
methylcellulose). Vehicle-treated mice developed carotid artery
thrombosis within a mean occlusion time of 57.8.+ 7.5 min, while
splitomicin-treated mice occluded within a mean time period of
31.2+5.3 min (n ¼ 7; P, 0.05; Figure 6A). Initial blood flow in
carotid artery did not differ between vehicle- and splitomicin-treated
mice (0.54+0.05 vs. 0.52+0.05 mL/min; n ¼ 7; P ¼ NS; Figure 6B).
Splitomicin treatment increased TF activity in mouse carotid artery
in vivo as compared with the controls (n ¼ 6; P, 0.05; Figure 6C).
Figure 3 Sirt1 inhibition induces endothelial TF expression at the
transcriptional level. (A and B) Real-time rtPCR reveals that splitomi-
cin and sirtinol enhance TNF-a-induced TF mRNA expression
(*P, 0.05 vs. TNF-a alone for splitomicin; *P, 0.05 vs. TNF-a
alone for sirtinol). (C) Sirt1 siRNA enhances TNF-a-induced TF
mRNA expression (*P, 0.01 vs. TNF-a alone).
Figure 4 Sirt1 inhibition increases TF promoter activity. (A and B)
TNF-a increases the activity of the minimal TF promoter. Splitomicin
(A) and sirtinol (B) enhance TF promoter activity under
cytokine-induced conditions (*P, 0.01 vs. TNF-a alone). AU, arbi-
trary units.
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4. Discussion
The present study demonstrates that Sirt1 inhibits TF expression at the
transcriptional level via NFkB/p65 in human vascular cells. Further-
more, it shows that inhibition of Sirt1 induces thrombus formation
and arterial TF activity in vivo.
To inhibit Sirt1 activity in human vascular cells, two different
pharmacological agents were applied. Both splitomicin and sirtinol
are established inhibitors of Sirt1.11,28– 30 It is still debated to what
extent these drugs specifically inhibit Sirt1; indeed, sirtinol may also
inhibit Sirt2.30 Nevertheless, the concentrations of both substances
applied in this study are within the established range.17,19 Moreover,
splitomicin did not alter TF expression in Sirt12/2 MEFs, and TF
was increased when Sirt1 was down-regulated by siRNA. Hence,
these data support the conclusion that Sirt1 regulates the expression
of TF.
Cytokine-mediated TF expression is mainly regulated at the tran-
scriptional level, where NFkB/p65 is importantly involved.2 Transcrip-
tionally active NFkB consists of a heterodimeric complex mainly
composed of a p65 and a p50 subunit. In quiescent cells, NFkB is
retained in the cytoplasm by its inhibitor IkB. Upon cytokine stimu-
lation, IkB becomes degraded allowing NFkB to translocate to the
nucleus and to stimulate gene transcription. In this study, both Sirt1
inhibitors enhanced nuclear translocation and DNA binding of NFkB/
p65, identifying NFkB/p65 as a downstream target of Sirt1 in the
context of TF expression. Since the Sirt1 inhibitors did not affect
MAP kinases nor IkB degradation, an involvement of these mediators
can be ruled out; thus, a direct effect of Sirt1 on NFkB/p65 seems
Figure 5 Sirt1 inhibition enhances NFkB/p65 activation via acetylation of Lys310 of NFkB/p65. (A and B) TNF-a stimulates NFkB/p65 DNA binding
activity as compared with control conditions. Splitomicin and sirtinol both enhance NFkB/p65 DNA binding (*P, 0.01 vs. TNF-a alone). (C) Sirt1
siRNA induces TF mRNA up-regulation in the presence of wild-type NFkB/p65, whereas its expression is reduced by a non-acetylatable Lys310-mutant
NFkB/p65 (*P, 0.01 vs. wild-type NFkB/p65). (D) Sirt1 protein down-regulation by specific siRNA is demonstrated. (E) NFkB/p65 immunoprecipita-
tion in HAECs reveals more acetylated Lys310 NFkB/p65 upon Sirt1 siRNA treatment.
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likely. Acetylation of Lys310 and Lys221 residues of NFkB/p65 impairs its
association with IkB and increases its DNA-binding capacity.31 Sirt1
deacetylates Lys310 of the NFkB/p65 subunit in different cell types
and thereby blunts NFkB/p65-mediated gene expression.17,32 Exper-
iments involving NFkB/p652/2 MEFs reconstituted with either wild-
type NFkB/p65 or non-acetylatable Lys310-mutant NFkB/p65, respect-
ively, demonstrate that regulation of TF mRNA expression by Sirt1
indeed depends on Lys310 acetylation of NFkB/p65. Nevertheless,
other downstream targets of Sirt1, such as eNOS or p53, are also
known to regulate TF expression,33,34 and a role of these regulators
in Sirt1-mediated TF expression in addition to that of NFkB/p65
cannot be ruled out by the current data.
TF is the key initiator of coagulation and therefore an important
trigger of thrombosis.35 Exposure of TF to the circulating blood
results in acute thrombosis and eventually vascular occlusion; in
fact, reducing TF expression impairs thrombus formation.36 To inves-
tigate arterial thrombosis in vivo, a photochemical vascular injury
model was used, since it is an established method to study
TF-dependent thrombus formation.36 Mean occlusion time in
splitomicin-treated mice was reduced by nearly 50%, supporting the
concept that inhibition of Sirt1 induces arterial thrombosis. The
increased TF activity in mouse carotid artery indicates that Sirt1 inhi-
bition regulates thrombosis at least in part via activation of TF in vivo.
TFPI, the physiological inhibitor of TF, was not affected by splitomicin
treatment excluding compensatory effects on TF activity. Given the
importance of the balance between TF and TFPI for thrombosis,37
these findings underscore a role for TF in the modulation of thrombus
formation by Sirt1. Hence, Sirt1 activators, which are currently under
investigation for the treatment of type 2 diabetes mellitus, may
possess additional protective cardiovascular effects by inhibiting arter-
ial thrombus formation.
Sirt1 inhibition resulted in an enhanced TF expression after stimu-
lation with different mediators. Hence, Sirt1 may suppress TF
expression especially in the inflammatory environment observed in
patients exposed to cardiovascular risk factors and with advanced
atherosclerotic lesions.38 Indeed, elevated levels of soluble TF are
observed in patients with atherosclerosis as compared with con-
trols.39 Furthermore, even higher concentrations are measured in
the area around the culprit lesion in patients with unstable angina
or acute myocardial infarction as compared with patients with
stable angina.6,40 Taken together, pharmacological or genetic acti-
vation of Sirt1 could be a promising therapeutic target in these
conditions.
A recent report described that endothelial overexpression of Sirt1
diminishes atherogenesis in ApoE-deficient mice, suggesting an anti-
atherosclerotic effect of Sirt1.21 In addition, Sirt1 exerts beneficial
effects on cardiovascular risk factors such as type 2 diabetes mellitus
and arterial hypertension.22,41,42 Sirt1 also mediates the effects of
caloric restriction on life-span extension,43 which may in turn
improve endothelial function and blood pressure regulation.44 Since
TF expression and activity is increased by cardiovascular risk factors
such as type 2 diabetes mellitus45,46 and arterial hypertension,47
Sirt1 activators, which are currently under investigation in clinical
trials for the treatment of cardiovascular risk factors, could exert a
dual beneficial effect preventing arterial thrombosis not only by
down-regulating TF expression, but also by interfering with the risk
factors inducing it.
In summary, this study demonstrates that Sirt1 inhibition enhances
TF in vitro as well as in vivo, and accelerates arterial thrombus for-
mation. Sirt1 exerts these effects at the transcriptional level by mod-
ulating NFkB/p65 DNA binding without affecting MAP kinase
activation. These findings reveal a novel action of Sirt1 and suggest
that Sirt1 activators may be applied for the prevention of
thrombosis.
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Supplementary Material 
 
Figure legends 
 
Supplemental figure 1: Sirt1 inhibitors are not cytotoxic 
LDH assay confirms that splitomicin (A) and sirtinol (B) do not induce cell death 
(P=NS for all concentrations). 
 
Supplemental figure 2: Splitomicin is Sirt1 specific 
A. Splitomicin on top of trichostatin A (TSA) reduces HDAC activity in 
endothelial cells (*P<0.05 vs TSA alone). AFU: Arbitrary fluorescent units. B. 
Splitomicin does not affect TF protein expression in Sirt1-/- MEFs (P=NS vs control).   
 
Supplemental figure 3: Sirt1 activation inhibits TF protein and mRNA 
expression  
A and B. Resveratrol decreases TNF-α induced TF mRNA expression 
(*P<0.05) and TF protein expression (*P<0.01). C. Sirt1 overexpression in Sirt1-/- 
MEFs decreases cytokine induced TF mRNA expression (*P<0.01). 
 
Supplemental figure 4: Splitomicin treatment does not alter MAP kinase 
activation nor IκB-α  degradation 
TNF-α induces a transient phosphorylation of the MAP kinases p38, JNK, and 
ERK. Splitomicin does not affect phosphorylation (P=NS vs TNF-α alone for each 
time point) nor TNF-α induced transient IκB-α degradation (P=NS vs TNF-α alone for 
each time point). 
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Supplemental figure 5: Sirtinol treatment does not alter MAP kinase activation 
nor IκB-α  degradation 
TNF-α induces a transient phosphorylation of the MAP kinases p38, JNK, and 
ERK. Sirtinol does not affect phosphorylation (P=NS vs TNF-α alone for each time 
point) nor TNF-α induced transient IκB-α degradation (P=NS vs TNF-α alone for 
each time point). 
 
Supplemental figure 6: Sirt1 inhibition enhances NFκB/p65 translocation 
Immunofluorescence staining for p65 reveals increased nuclear translocation of 
NFκB/p65 after splitomicin treatment (P<0.01). 
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Figure 1A: TF protein expression in splitom
icin-treated cells
Control
TNF-a
DM
SO+TNF-a
Splito (25uM
)+TNF-a
Splito (50uM
)+TNF-a
Splito (100uM
)+TNF-a
Splito (200uM
)+TNF-a
M
ean
0.03
100.00
107.80
365.60
479.60
557.40
534.40
Std. Deviation
0.049
0.00
23.80
138.30
244.60
293.90
254.90
P-value vs TNF-a
<0.05
-
NS
NS
<0.05
<0.01
<0.01
Statistical test
One-way ANOVA
Figure 1B: TF activity in splitom
icin-treated cells
Control
TNF-a
Splito+TNF-a
M
ean
0.0129
0.1243
0.2502
Std. Deviation
0.0039
0.0585
0.0139
P-value vs TNF-a
<0.01
-
<0.01
Statistical test
One-way ANOVA
Figure 1C: TF protein expression in sirtinol-treated cells
Control
TNF-a
DM
SO+TNF-a
Sirti (15uM
)+TNF-a
Sirti (30uM
)+TNF-a
Sirti (60uM
)+TNF-a
M
ean
6.55
100.00
89.03
171.10
201.00
194.00
Std. Deviation
9.14
0.00
13.40
83.47
86.84
56.06
P-value vs TNF-a
<0.05
-
NS
NS
<0.05
<0.05
Statistical test
One-way ANOVA
Figure 1D: TF activity in sirtinol-treated cells
Control
TNF-a
Sirti+TNF-a
M
ean
0.0130
0.1278
0.2184
Std. Deviation
0.0089
0.0264
0.0052
P-value vs TNF-a
<0.01
-
<0.01
Statistical test
One-way ANOVA
Figure 1E: TF protein expression in Sirt1 siRNA-treated cells
Scr
Sirt1 siRNA
Scr+TNF-a
Sirt1 siRNA+TNF-a
M
ean
0.01
4.67
100.00
157.70
Std. Deviation
0.01
5.02
0.00
22.31
P-value vs scr+TNF-a
<0.01
<0.01
-
<0.01
Statistical test
One-way ANOVA
Figure 1F: Sirt1 downregulation by siRNAScr
Sirt1 siRNA
Scr+TNF-a
Sirt1 siRNA+TNF-a
M
ean
100.00
56.67
95.92
53.83
Std. Deviation
0.00
10.08
7.71
9.08
P-value vs scr
-
<0.01
-
-
P-value vs scr+TNF-a
-
-
-
<0.01
Statistical test
One-way ANOVA
Figure 2A: TF protein expression by different stim
ulations in splitom
icin-treated cells
Control
TNF-a
Hist
Thr
Splito+TNF-a
Splito+Hist
Splito+Thr
M
ean
1.343
100.00
43.24
57.88
307.00
161.00
334.10
Std. Deviation
2.685
0.00
3.44
19.48
54.73
10.92
129.10
P-value vs TNF-a
-
-
-
-
<0.01
-
-
P-value vs Hist
-
-
-
-
-
<0.05
-
P-value vs Thr
-
-
-
-
-
-
<0.01
Statistical test
One-way ANOVA
Figure 2B: TFPI protein expression in splitom
icin-treated cells
Control
TNF-a
DM
SO+TNF-a
Splito (25uM
)+TNF-a
Splito (50uM
)+TNF-a
Splito (100uM
)+TNF-a
Splito (200uM
)+TNF-a
M
ean
124.30
100.00
103.50
109.20
102.20
139.80
146.30
Std. Deviation
68.04
0.00
46.47
21.37
50.43
71.44
59.58
P-value vs TNF-a
NS
-
NS
NS
NS
NS
NS
Statistical test
One-way ANOVA
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Figure 2C: Endogenous Sirt1 expressionControl
TNF-a
M
ean
100.00
92.75
Std. Deviation
0.00
18.03
P-value vs control
-
NS
Statistical test
T-test
Figure 3A: TF m
RNA expression in splitom
icin-treated cells
Control
TNFa
DM
SO+TNF-a
Splito (25uM
)+TNF-a
Splito (50uM
)+TNF-a
Splito (100uM
)+TNF-a
Splito (200uM
)+TNF-a
M
ean
0.0000200
0.0005905
0.0005058
0.0010530
0.0011120
0.0011130
0.0010950
Std. Deviation
0.0000044
0.0001872
0.0001612
0.0003250
0.0003573
0.0003300
0.0003522
P-value vs TNF-a
<0.05
-
NS
NS
<0.05
<0.05
<0.05
Statistical test
One-way ANOVA
Figure 3B: TF m
RNA expression in sirtinol-treated cells
Control
TNF-a
DM
SO+TNF-a
Sirti (15uM
)+TNF-a
Sirti (30uM
)+TNF-a
Sirti (60uM
)+TNF-a
M
ean
0.0000940
0.0006356
0.0005390
0.0009813
0.0011940
0.0012280
Std. Deviation
0.0000647
0.0001872
0.0002795
0.0003944
0.0002461
0.0005392
P-value vs TNF-a
<0.05
-
NS
NS
<0.05
<0.05
Statistical test
One-way ANOVA
Figure 3C: TF m
RA expression in Sirt1 siRNA-treated cells
Scr
Sirt1 siRNA
Scr+TNF-a
Sirt1 siRNA+TNF-a
M
ean
0.0000230
0.0000250
0.0004957
0.0011370
Std. Deviation
0.0000078
0.0000056
0.0003381
0.0004513
P-value vs scr+TNF-a
<0.05
<0.05
-
<0.01
Statistical test
One-way ANOVA
Figure 4A: TF prom
oter activity in splitom
icin-treated cells
Control
Control+TNF-a
Control+TNF-a+splito
EV
EV+TNF-a
EV+TNF-a+splito
AD
AD+TNF-a
AD+TNF-a+splito
M
ean
220.00
160.00
702.50
362.50
795.00
626.70
452.50
1601.00
2871.00
Std. Deviation
382.60
358.20
918.70
449.30
264.30
594.10
521.20
329.10
559.20
P-value vs AD+TNF-a
<0.01
<0.01
NS
<0.01
NS
NS
<0.05
-
<0.01
Statistical test
One-way ANOVA
Figure 4b: TF prom
oter activity in sirtinol-treated cells
Control
Control+TNF-a
Control+TNF-a+sirti
EV
EV+TNF-a
EV+TNF-a+sirti
AD
AD+TNF-a
AD+TNF-a+sirti
M
ean
92.00
230.00
234.00
294.00
1112.00
1020.00
602.00
2565.00
4438.00
Std. Deviation
102.60
121.40
100.10
189.00
595.00
735.70
359.80
741.70
1363.00
P-value vs AD+TNF-a
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
-
<0.01
Statistical test
One-way ANOVA
Figure 5A: NFkB-DNA-binding in splitom
icin-treated cells
Control
TNF-a
Splito+TNFa
M
ean
0.0953
0.2134
0.2741
Std. Deviation
0.0278
0.0160
0.0319
P-value vs TNF-a
<0.01
-
<0.01
Statistical test
One-way ANOVA
Figure 5B: NFkB-DNA-binding in sirtinol-treated cells
Control
TNF-a
Sirti+TNFa
M
ean
0.0239
0.1830
0.2951
Std. Deviation
0.0063
0.0364
0.0593
P-value vs TNF-a
<0.01
-
<0.01
Statistical test
One-way ANOVA
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Figure 5C: Fibroblast TF m
RNA expression in Sirt1 siRNA-treated cells
Scr+TNF-a; wt-p65
Sirt1+TNF-a; wt-p65
Scr+TNF-a; mut-p65
Sirt1+TNF-a; mut-p65
M
ean
0.8880
1.1330
0.6215
0.8195
Std. Deviation
0.1199
0.1470
0.1160
0.1400
P-value vs Sirt1 siRNA+TNF-a; wt-p65
<0.05
-
<0.01
<0.01
Statistical test
One-way ANOVA
Figure 5D: Sirt1 downreglation in M
EFs
Scr+TNF-a; wt-p65
Sirt1+TNF-a; wt-p65
Scr+TNF-a; mut-p65
Sirt1+TNF-a; mut-p65
M
ean
100.00
28.86
123.80
38.00
Std. Deviation
0.00
5.93
22.77
1.76
P-value vs scr+TNF-a; wt-p65
-
<0.05
-
-
P-value vs scr+TNF-a; mut-p65
-
-
-
<0.05
Statistical test
One-way ANOVA
Figure 6A: Tim
e to occlusion
Vehicle
Splitomicin
M
ean
57.8
31.2
Std. Deviation
7.5
5.3
P-value vs vehicle
-
<0.05
Statistical test
T-test
Figure 6B: Initial blood flow
Vehicle
Splitomicin
M
ean
0.54
0.52
Std. Deviation
0.05
0.05
P-value vs vehicle
-
NS
Statistical test
T-test
Figure 6C: TF activity
Vehicle
Splitomicin
M
ean
0.03343
0.05701
Std. Deviation
0.00907
0.02061
P-value vs vehicle
-
<0.05
Statistical test
T-test
Supplem
ental figure 1A: LDH release in splitom
icin-treated cells
Control
TNF-a (5ng/ml)
Splito (25uM
)+TNF-a
Splito (50uM
)+TNF-a
Splito (100uM
)+TNF-a
Splito (200uM
)+TNF-a
M
ean
100.00
100.60
89.11
94.00
88.90
88.52
Std. Deviation
0.00
9.35
6.11
5.58
11.07
13.01
P-value vs Control
-
NS
NS
NS
NS
NS
Statistical test
One-way ANOVA
Supplem
ental figure 1B: LDH release in sirtinol-treated cells
Control
TNF-a
Sirti (15uM
)+TNF-a
Sirti (30uM
)+TNF-a
Sirti (60uM
)+TNF-a
M
ean
100.00
103.40
88.57
73.47
88.18
Std. Deviation
0.00
23.57
24.10
10.62
10.40
P-value vs Control
-
NS
NS
NS
NS
Statistical test
One-way ANOVA
Supplem
ental figure 2A: HDACIII activity
TSA
TSA+splito
M
ean
7841
4026
Std. Deviation
1032
651.8
P-value vs TSA
-
<0.05
Statistical test
T-test
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Supplem
ental figure 2B: TF protein expression in splitom
icin-treated M
EFs 
TNF-a
Splito+TNF-a
M
ean
100.00
103.10
Std. Deviation
0.00
16.87
P-value vs TNF-a
-
NS
Statistical test
T-test
Supplem
ental figure 3A: TF protein expression in resveratrol-treated HAECs
Control
TNF-a
DM
SO+TNF-a
Resv (10uM
)+TNF-a
Resv (20uM
)+TNF-a
Resv (40uM
)+TNF-a
M
ean
0.00
100.00
109.70
24.22
24.38
10.42
Std. Deviation
0.00
0.00
18.21
9.71
9.82
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Supplem
ental figure 3B: TF m
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Supplem
ental figure 3C: Sirt1-overexpression inhibits TF expression
Control
Sirt1
TNF-a
Sirt1+TNF-a
M
ean
0.0550600
0.0496500
0.0741500
0.0533400
Std. Deviation
0.0035640
0.0083850
0.0002964
0.0019810
P-value vs TNF-a
<0.01
<0.01
-
<0.01
Statistical test
One-way ANOVA
Supplem
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ApoE2/2 PGC-1a2/2Mice Display Reduced IL-18 Levels
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Abstract
Background: Atherosclerosis is a chronic inflammatory disease that evolves from the interaction of activated endothelial
cells, macrophages, lymphocytes and modified lipoproteins (LDLs). In the last years many molecules with crucial metabolic
functions have been shown to prevent important steps in the progression of atherogenesis, including peroxisome
proliferator activated receptors (PPARs) and the class III histone deacetylase (HDAC) SIRT1. The PPARc coactivator 1 alpha
(Ppargc1a or PGC-1a) was identified as an important transcriptional cofactor of PPARc and is activated by SIRT1. The aim of
this study was to analyze total PGC-1a deficiency in an atherosclerotic mouse model.
Methodology/Principal Findings: To investigate if total PGC-1a deficiency affects atherosclerosis, we compared ApoE2/2
PGC-1a2/2 and ApoE2/2 PGC-1a+/+ mice kept on a high cholesterol diet. Despite having more macrophages and a higher
ICAM-1 expression in plaques, ApoE2/2 PGC-1a2/2 did not display more or larger atherosclerotic plaques than their ApoE2/2
PGC-1a+/+ littermates. In line with the previously published phenotype of PGC-1a2/2 mice, ApoE2/2 PGC-1a2/2 mice had
marked reduced body, liver and epididymal white adipose tissue (WAT) weight. VLDL/LDL-cholesterol and triglyceride
contents were also reduced. Aortic expression of PPARa and PPARc, two crucial regulators for adipocyte differentitation and
glucose and lipid metabolism, as well as the expression of some PPAR target genes was significantly reduced in ApoE2/2
PGC-1a2/2 mice. Importantly, the epididymal WAT and aortic expression of IL-18 and IL-18 plasma levels, a pro-
atherosclerotic cytokine, was markedly reduced in ApoE2/2 PGC-1a2/2 mice.
Conclusions/Significance: ApoE2/2 PGC-1a2/2 mice, similar as PGC-1a2/2 mice exhibit markedly reduced total body and
visceral fat weight. Since inflammation of visceral fat is a crucial trigger of atherogenesis, decreased visceral fat in PGC-1a-
deficient mice may explain why these mice do not develop enhanced atherosclerosis.
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Introduction
Atherosclerosis is a chronic inflammatory disease that results
from interaction between activated endothelial cells, modified low-
density lipoproteins (LDL), monocyte-derived macrophages, T cells,
and the vessel wall. Activated endothelial cells express adhesion
molecules that attract and recruit blood monocytes and lympho-
cytes. Upon binding to the endothelial layer, these monocytes
transmigrate into the subintimal space, and differentiate into
macrophages. Plaque macrophages interact with lymphatic cells,
mainly T cells, ingest modified LDL via scavenger receptors and
become foam cells, thereby promoting plaque formation [1].
PGC-1a was the first described member of the small PGC-1
family of coactivators [2]. Other members of this protein family
are PGC-1b and PGC-related coactivator (PRC). PGC-1a is an
important cofactor in the transcriptional regulation of genes
encoding metabolic enzymes and mitochondrial proteins [3], and
it is interacting with many different transcription factors, such as
peroxisome proliferator activated receptors (PPARs, including
PPARa, PPARb/d, and PPARc), Liver X receptor a and b
(LXRa and LXRb), Glucagon receptor (GR), and Forkhead box
O1 (FoxO1) [4,5,6,7,8,9,10].
The phenotype of PGC-1a knock-out mice underlines the
central role of this transcription cofactor in homeostatic control of
metabolism: they are leaner than wild-type (WT) littermates, have
markedly reduced body fat content, and are resistant to diet-
induced obesity, hence protected from developing insulin
resistance and impaired glucose tolerance [11]. This difference is
explained by their CNS-linked hyperactivity and is not a
consequence of altered food intake [11].
Overexpression of PGC-1a in human aortic smooth muscle and
endothelial cells in vitro has been shown to prevent reactive oxygen
species (ROS) production and NAD(P)H oxidase activity, with
subsequently reduced NF-kB activity and lower expression levels
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of MCP-1 and VCAM-1 [12], which are important triggers of
inflammation and atherosclerosis. Moreover, PGC-1a overexpres-
sion in endothelial cells prevented alpha-linoleic acid-induced
ROS formation in vitro and improved endothelial dysfunction in
aortic rings ex vivo [13].
The following studies suggest a link between PGC-1a and
atherogenesis at the clinical level: Xie et al. reported a correlation
between PGC-1a polymorphism and hypertension [14], and
Zhang et al. showed an association between PGC-1a polymor-
phism and the prevalence of coronary artery disease [15].
Thus, we investigated the effects of PGC-1a deficiency on
atherogenesis by comparing ApoE2/2 PGC-1a2/2 and ApoE2/2
PGC-1a+/+ mice.
Results
Total PGC-1a2/2 deletion does not affect atherogenesis
To study the potential role of PGC-1a in atherogenesis, we
crossed PGC-1a2/2 with ApoE2/2 mice, and compared 20-week
old male ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+ mice that
were kept on a high-cholesterol diet for 12 weeks. Histomor-
phometry of thoraco-abdominal aortae stained with Oil-Red O
(ORO) revealed no difference in atherosclerotic plaque area
between ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+ mice
(Fig. 1A). Advanced plaque parameters also revealed a similar total
collagen content, plaque diameter or cap thickness in plaques of the
aortic sinus that were stained with Elastica van Gieson (Fig. 1B-F).
Increased macrophage and ICAM-1 expression in ApoE2/2
PGC-1a2/2 mice
To further analyze cellular and molecular mediators in the
progression of atherosclerosis, we quantified the amount of lipids,
macrophages, T cells, as well as of the adhesion molecules ICAM-
1 and VCAM-1 in plaques from the aortic sinus. No difference in
lipid content, CD3-positive T cells, and VCAM-1 expression was
observed between ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+
mice. However, more CD68-positive macrophages and ICAM-1-
Figure 1. Atherosclerotic lesions and features of plaque vulnerability in ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+ mice. En face
plaque quantification of thoraco-abdominal aortae stained with ORO (A). Absolute values of plaque collagen content (B), necrotic core size (C) and
cap thickness (D) in plaques from the aortic sinus. Relative values of the necrotic core and fibrous cap size on plaque diameter (E), and representative
images to show how the necrotic core (blue line) and fibrous cap (black line) in plaques from the aortic sinus was measured (F). A: ApoE2/2 PGC-1a+/+
n= 13 (open circles); ApoE2/2 PGC-1a2/2 n=14 (closed circles). B-E: n = 10. ApoE2/2 PGC-1a2/2 (2/2) and ApoE2/2 PGC-1a+/+ (+/+).
doi:10.1371/journal.pone.0013539.g001
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expressing cells were detected in plaques from ApoE2/2 PGC-1a2/2
mice (Fig. 2).
ApoE2/2 PGC-1a2/2 mice exhibit reduced total body
weight, epididymal white adipose tissue weight, and
VLDL/LDL-cholesterol and VLDL/LDL-triglyceride
contents
ApoE2/2 PGC-1a2/2 mice had a lower body, liver, and
epididymal fat weight than ApoE2/2 PGC-1a+/+ mice (Fig. 3A–
D). Spleen weight did not differ between the two groups (Fig. 3E).
These data match the published phenotype of PGC-1a2/2 mice
[11]. We next analyzed total cholesterol and triglyceride plasma
levels and their distribution in lipoprotein fractions. Both
cholesterol and triglyceride contents were lower in VLDL and
IDL/LDL particles, whereas their content in HDL particles did
not differ (Fig. 4A, B). Total plasma cholesterol showed a clear
trend, whereas total triglyceride levels were markedly lower in
ApoE2/2 PGC-1a2/2 compared to ApoE2/2 PGC-1a+/+ mice
(Fig. 4C).
Reduced expression of PPAR and PPAR target genes
Peroxisome proliferator activated receptors (PPARs) are impor-
tant regulators of adipocyte differentiation as well as lipid
metabolism and inflammation and their transcription is regulated
by PGC-1a [6,16,17]. mRNA expression PPARa and PPARc was
reduced in aortic lysates of ApoE2/2 PGC-1a2/2 mice (Fig. 5A),
whereas PPARb/d levels were not changed (Fig. 5A). To examine
if the differential expression of these transcriptional regulators
exert functional effects, we quantified the expression of some
PPARa and/or PPARc target genes: Adipoq (adiponectin), Cebpa (C/
EBP-a), Fabp4 (aP2), Fasn (Fatty acid synthase), Fatp1 (Fatty acid
transport protein 1), Lipe (Hormone-sensitive lipase), Lpl (Lipoprotein lipase),
Figure 2. Characterization of plaque inflammation. Quantitative analysis of lipid content in aortic sinus (A; Oil red-O staining), macrophage
immunoreactivity (B; CD68-positive cells), T cell number (C; CD3-positive cells; scale bar, 200 mm), VCAM-1 (D) and ICAM-1 (E) immunoreactivity in
plaques of the aortic sinus of ApoE2/2 PGC-1a2/2 (2/2) and ApoE2/2 PGC-1a+/+ (+/+) mice expressed as a proportion of the total plaque areas. n = 10
per genotype. * p,0.05. **p,0.01.
doi:10.1371/journal.pone.0013539.g002
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LXR-a (Liver X receptor a), Pck1 (Phosphoenolpyruvate carboxykinase 1),
and Ucp1 (Uncoupling protein 1). Expression of Cebpa, Fabp4, Pck1,
and Ucp1 was significantly lower in ApoE2/2 PGC-1a2/2
compared to ApoE2/2 PGC-1a+/+ mice, while the expression of
Fasn showed the same trend and mRNA levels of Adipoq, Fatp1,
Lipe, Lpl, and LXR-a did not differ (Fig. 5B). These data suggest
that PPARa and PPARc expression and function may at least in
part be suppressed in ApoE2/2 PGC-1a2/2 mice.
Expression of IL-18 in epididymal WAT from ApoE2/2
PGC-1a2/2 mice is markedly reduced
Mice transplanted with visceral fat develop more atherosclerosis
than sham-operated animals [18], supporting the clinical concept
that that visceral fat as well as its inflammatory mediators are an
important risk factors of atherosclerosis and acute coronary events
[19,20]. We therefore analyzed the expression of adipose tissue-
derived hormones and cytokines in ApoE2/2 PGC-1a2/2 and
ApoE2/2 PGC-1a+/+ mice. While expression of Adipoq, Nampt
(Nicotinamide phosphoribosyltransferase), Retn (Resistin), IL-6, IL-10,
TGF-b, MCP-1, IFN-c, Agt (Angiotensinogen), 11b-HSD1 (11-beta-
hydroxysteroid dehydrogenase 1), TNFa, and Lpl was only mildly reduced
or unchanged, the expression of leptin, Rarres2 (chemerin), Serpine1
(PAI-1), and IL-18 was lower, and expression of complement factor D
(Cfd or adipsin) higher in ApoE2/2 PGC-1a2/2 compared to
ApoE2/2 PGC-1a+/+ epididymal WAT (Fig. 6).
Reduced expression of IL-18 and CXL16 in aortic lysates
from ApoE2/2 PGC-1a2/2 mice
The reduced expression of IL-18 in epididymal WAT is of
special interest, since ApoE2/2 IL-182/2 mice develop less
atherosclerosis than control ApoE2/2 mice [21]. Importantly,
injection of IL-18 into SCID/apoE kockout mice elevated levels of
Figure 3. Total body weight and adipose tissue mass. ApoE2/2 PGC-1a2/2 exhibit a lower body weight (A), liver weight (B), as well as total
epididymal (C) and percent epididymal fat of body weight (D) than ApoE2/2 PGC-1a+/+ mice. No difference is observed in spleen weight (E). n$14 per
genotype. * p,0.05; *** p,0.001.
doi:10.1371/journal.pone.0013539.g003
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IFN-c and scavenger receptor for phosphatidylserine and oxidized
lipoprotein/CXC chemokine ligand 16 (SR-PSOX/CXCL16) in
atherosclerotic lesions [22]. Measurement of these factors in aortic
tissue, revealed that IL-18 and SR-PSOX/CXCL16 mRNA levels
were reduced in ApoE2/2 PGC-1a2/2mice, while IFN-c expression
did not differ between the two genotypes (Fig. 7A). We also
quantified the amount of IL-18 and soluble SR-PSOX/CXCL16 in
plasma samples. In line with the reduced expression in epididymal
WAT and aortae, IL-18 protein level was also reduced in the plasma
of ApoE2/2 PGC-1a2/2 compared to ApoE2/2 PGC-1a+/+ mice
(Fig. 7B). In contrast, plasma levels of secreted SR-PSOX/CXCL16
did not differ between the two genotypes (Fig. 7B).
Discussion
Our data show that ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-
1a+/+ mice do not differ with regard to atherosclerosis, features of
plaque vulnerability, expression of VCAM-1, and T cells number.
Increased expression of ICAM-1 or CD68-positive cells in plaques
of ApoE2/2 PGC-1a2/2 do not appear to play a substantial role as
they do not affect plaque size. Importantly, the double knockout
mice are leaner, have lighter liver and epididymal fat, and less
cholesterol and triglycerides in VLDL and LDL subfractions. In
addition, aortic expression of PPARa and PPARc as well as some of
their target genes is reduced in ApoE2/2 PGC-1a2/2 mice.
This phenotype is in line with the first study that described the
phenotype of PGC-1a2/2 mice, which also have markedly reduced
body fat content [11]. Because visceral (epididymal) WAT
inflammation contributes to disease progression [18], it is not
astonishing that we observed no difference in plaque lesions
between ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+ mice.
Beyond this notion, our data propose that total PGC-1a deficiency
may rescue an increased atherosclerotic phenotype because of the
reduced paracrine effects mediated by the visceral fat.
The lower aortic expression of PPARa and PPARc as well as of
PPAR target genes proposes that the function of these two PPARs is
suppressed in ApoE2/2 PGC-1a2/2 mice. Interestingly, both
PPARa and PPARc can exert anti-atherogenic functions in the
Figure 4. Plasma lipid levels. (A, B) Cholesterol and triglyceride
distribution in the plasma lipoprotein fractions of ApoE2/2 PGC-1a2/2
and ApoE2/2 PGC-1a+/+ mice. Plasma samples were pooled (n = 14 per
genotype) and fractionated on a HPLC column. (C) Total cholesterol and
triglycerides concentrations were measured with an enzymatic color-
imetric assay. n = 14 per genotype. HPLC, high pressure liquid
chromatography; HDL, high-density lipoproteins; IDL, intermediate-
density lipoproteins; LDL, low-density lipoproteins; VLDL, very-low-
density lipoproteins. ** p,0.01.
doi:10.1371/journal.pone.0013539.g004
Figure 5. Expression of PPAR and PPAR target genes. (A) Reduced
aortic mRNA expression of PPARa and PPARc, but unchanged expression
of PPARb/d in ApoE2/2 PGC-1a2/2 compared to ApoE2/2 PGC-1a+/+ mice.
(B) Aortic mRNA expression of Adipoq, Cebpa, Fabp4, Fasn, Fatp, Lipe, Lpl,
LXR-a, Pck1, and Ucp1. n$9 per genotype. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0013539.g005
PGC-1a in Atherosclerosis
PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13539 
- 93 -
arterial wall. For example, administration of the PPARc ligand
rosiglitazone reduces foam cell formation and atherosclerosis in
LDL-R knockout mice [23], and transplantation of PPARc-deficient
bone marrow into recipient LDL-R knockout mice enhanced
atherosclerosis [24]. One of the main atherogenic targets of PPARc
is LXRa [24,25], whose expression was not changed between
ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+ aortic lysates.
Reduced expression of Rarres2 (chemerin), Serpine1 (PAI-1), and IL-
18 in visceral adipose tissue could be sufficient to avoid increased
atherogenesis. Rarres2 is associated with white adipose tissue
inflammation and promotes mobilization and chemotaxis of
dendritic cells and macrophages [26,27]. While its expression
correlates with inflammatory markers, such as C-reactive protein,
it does not predict atherosclerosis in humans [28]. Nevertheless, an
atherogenic contribution of Rarres2 cannot be excluded.
PAI-1 is an anti-fibrinolytic enzyme and has beneficial and
deleterious effects in atherogenesis. For example, PAI-1-deficient
mice showed attenuated neointima formation after perivascular
cuff-induced injury [29], and local PAI-1 overexpression prevented
the development of abdominal aortic aneurysm [30]. On the other
hand, PAI-1 levels are elevated in various cardiovascular diseases
and associated with atherothrombosis [31].
The lowest expression of the tested cytokines in the visceral WAT
of ApoE2/2 PGC-1a2/2 mice was observed for IL-18. IL-18 is a
pro-atherogenic cytokine: Overexpression of IL-18 binding protein
and direct injection of recombinant IL-18 accelerate atherogenesis,
whereas IL-18 deficiency diminishes plaque formation in ApoE2/2
mice [21,22,32,33]. Furthermore, elevated levels of plasma IL-18
are observed in patients with previous myocardial infarction and are
associated with the extent of coronary atherosclerosis [34,35]. We
did not only observe a reduced expression of IL-18 in epididymal
WAT, but also in aortic tissue and plasma samples of ApoE2/2 PGC-
1a2/2 mice. It is conceivable that the lower expression of IL-18
alone is sufficient to avoid an acceleration of atherogenesis in our
ApoE2/2 PGC-1a2/2 mouse model.
Interestingly, IL-18-mediated increase of atherosclerosis is accom-
panied by elevation of SR-PSOX/CXCL16 expression [22]. SR-
PSOX/CXCL16 is a membrane-bound scavenger receptor that
binds to the chemokine (C-X-C motif) receptor 6 on lymphocytes
[36,37,38,39]. This membrane-anchored chemokine can be further
cleaved by specific proteases, hence released in a soluble form
[40,41], which has been proposed as a biomarker for acute coronary
syndromes [42]. We observed reduced mRNA levels of SR-PSOX/
Figure 6. Expression of adipocyte-derived hormones and adipokines. Epididymal WAT mRNA expression in ApoE2/2 PGC-1a2/2 and
ApoE2/2 PGC-1a+/+ mice: Adipoq, Leptin, Nampt, Rarres2, Retn, Serpine1, IL-6, IL-10, IL-18, TGFb, MCP-1, Cfd, IFN-c, Agt, 11b-HSD1, TNFa and Lpl.
n = 11 per genotype. * p,0.05; 1 p,0.01, & p,0.001.
doi:10.1371/journal.pone.0013539.g006
Figure 7. Aortic and plasma expression levels of IL-18 and
CXCL16. (A) Reduced aortic mRNA expression of IL-18 and CXCL16, but
no change in the expression of IFN-c is observed in ApoE2/2 PGC-1a2/2
compared to ApoE2/2 PGC-1a+/+ mice. n$9 per genotype. (B) In plasma
samples only IL-18, but not CXCL16 protein levels differed between
ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+ mice. n$10 per genotype.
* p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0013539.g007
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CXCL16 in epididymal WAT and aortae of ApoE2/2 PGC-1a2/2
mice. However, protein levels of the soluble form of SR-PSOX/
CXCL16 in plasma did not differ between ApoE2/2 PGC-1a2/2 and
ApoE2/2 PGC-1a+/+ mice, suggesting that the proteolytic cleavage of
this chemokine is not affected in ApoE2/2 PGC-1a2/2 mice.
Cfd encodes adipsin, the mouse homolog of human complement
factor D, which is a serine protease that cleaves factor B in the
alternative complement pathway, and it is secreted at high levels in
adipose tissue [43,44,45]. While adipsin expression is increased in
catabolic conditions such as fasting, it is down-regulated in
different models of genetic and acquired obesity [46]. In line with
these observations, epididymal WAT expression of adipsin was
higher in ApoE2/2 PGC-1a2/2 compared to ApoE2/2 PGC-1a+/+
mice. Expression of adipsin and other components of the
alternative complement pathway correlate with atherosclerosis
[47], suggesting that the elevation of adipsin in ApoE2/2 PGC-
1a2/2 provides a pro-atherogenic contribution.
Atherosclerosis is a disease combining the complexity of lipid/
lipoprotein and inflammatory/immune disorders [48]. Since
PGC-1a is affecting these two important atherogenic systems, it
is difficult to dissect the functions of this enzyme in the chosen
animal model. For example, the reduced body weight and VLDL/
LDL-cholesterol and triglyceride contents as well as the dimin-
ished expression of IL-18 are certainly anti-atherogenic, whereas
the increased expression of adipsin may play a pro-atherogenic
role in ApoE2/2 PGC-1a2/2 mice. Further studies using tissue-
specific PGC-1a knockout or overexpression will be necessary to
address these questions in more detail.
Materials and Methods
Animals
ApoE2/2C57BL/6 [49]mice were crossed to PGC-1a2/2C57BL/
6 [11], to generate ApoE2/2 PGC-1a2/2 mice and ApoE2/2 PGC-
1a+/+ littermates. Of those, male mice were fed a high-cholesterol diet
(D12108: 40 kcal% fat, 1.25% cholesterol, Research Diets Inc.) for 12
weeks starting at the age of 8 weeks. Mice were weighted before being
sacrificed, and biopsies of aortae, heart, liver, spleen, brown and white
adipose tissue, and pancreas frozen in liquid nitrogen or OCT
(Optimal Cutting Temperature) for later analyses.
Ethics Statement
All animal procedures were approved by the local animal
committee (Kantonales Veterina¨ramt Zu¨rich, protocol no. 171/
2006) and performed in accordance with our institutional guidelines.
Immunohistochemistry
5 mm serial cryosections from the aortic sinus were stained with
rat anti-CD68, rat anti-CD3 (Abcam), rat anti-VCAM-1 (BD
Biosciences), rat anti-ICAM-1 (Serotec), or oil-red O (ORO).
Thoraco-abdominal aortae were fixed with 4% paraformaldehyde
and plaques stained with ORO for en face analysis. Collagen,
fibrous cap thickness, and necrotic core size were analyzed on
Elastica van Gieson (EVG)-stained cryosections of the aortic sinus
as described [50,51]. Means were taken from n= 10 different mice
evaluating 6 serial cryosections/tissue from each mouse.
RNA and protein analysis
Total RNA isolated from proximal aortae was extracted with
TRIZOL (Invitrogen), reverse transcribed with Ready-To-Go
You-Prime First-Strand Beads (GE Healthcare), and the cDNA
(n$9 per genotype) quantified by qPCR using SYBR Green
JumpStart Taq ReadyMix (Sigma-Aldrich). Primer sequences can
be found in the supplemental Table S1.
IL-18 and CXCL16 ELISA
Quantification of IL-18 and CXCL16 in plasma of mice where
performed with Mouse IL-18 Platinum ELISA kit (Bender
MedSystems) and Mouse CXCL16 ELISA kit (RayBiotech)
according to the manufacturers instructions. Plasma was diluted
1:2 for the IL-18, and 1:32 for the CXCL16 ELISA assay.
Cholesterol, triglycerides, and lipoprotein subfractioning
Total plasma cholesterol and triglycerides were quantified using
Infinity Cholesterol TR13421 and Infinity Triglycerides TR22421
(Thermo Electron Cooperation), respectively. The lipid distribu-
tion in plasma lipoprotein fractions was assessed by fast-
performance liquid chromatography gel filtration with a Tricorn
Superose 6 10/300 GL column (GE Healthcare) [52].
Statistical analyses
Data are presented as mean 6 SEM. The en face ORO
quantification was analyzed using a non-parametric Mann-
Whitney U t-test. Statistical significance of differences of all other
experiments was calculated using an unpaired Student’s t-test.
Significance was accepted at the level of p,0.05.
Supporting Information
Table S1 Primer sequences.
Found at: doi:10.1371/journal.pone.0013539.s001 (0.08 MB
PDF)
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Table S1 - Primer sequences 	  
Mouse gene name anti/sense Sequence (5’ to 3’) 
11β-HSD1 S CACTTATCTGAAGCCTCAAGGGCG 
11β-HSD1 A CCAATCCCTTTGCTGGCCCC 
Adiponectin (Adipoq) S AATCCTGCCCAGTCATGCCG 
Adiponectin (Adipoq) A CTTTCCTGCCAGGGGTTCCG 
Angiotensinogen (Agt) S TGCCCCAGCTGGAAATCCGA 
Angiotensinogen (Agt) A ATGGCGAACAGGAAGGGGCT 
Cebpa (C/EBP-α) S GTCACTGGTCAACTCCAGCA 
Cebpa (C/EBP-α) A TGGACAAGAACAGCAACGAG 
Cfd (Adipsin) S GCCCTACATGGCTTCCGTGC 
Cfd (Adipsin) A TGGGGACCCAACGAGGCATT 
Cxcl16 S GGGACAGAAGGCGCCACCAC 
Cxcl16 A CCCTGGTTGCCATCGCCTGG 
IFN-γ S ATCTGGAGGAACTGGCAAAA 
IFN-γ A TGAGCTCATTGAATGCTTGG  
IL-10 S CCAAGCCTTATCGGAAATGA 
IL-10 A TTTTCACAGGGGAGAAATCG 
IL-18 S ACAACTTTGGCCGACTTCAC 
IL-18 A TGGATCCATTTCCTCAAAGG 
IL-6 S CCTCTCTGCAAGAGACTTCCATCCA 
IL-6 A AGCCTCCGACTTGTGAAGTGGT 
Lep (leptin) S CAGCAGCTGCAAGGTGCAAG 
Lep (leptin) A GCCAGTGACCCTCTGCTTGG 
Lipe (Hormone-sensitive lipase) S GGGCCTGGCAGTGGTGTGTAAC 
Lipe (Hormone-sensitive lipase) A TGAGAACGCTGAGGCTTTGATCTTG 
Lpl S TTTGGCTCCAGAGTTTGACCGC 
Lpl A CGAAGGTCTTGCTGCTGTGGTT 
MCP-1 S ACTGAAGCCAGCTCTCTCTTCCTC 
MCP-1 A TTCCTTCTTGGGGTCAGCACAGAC 
Nampt (visfatin) S TCCCGAGGGCTCTGTCATCC 
Nampt (visfatin) A GCCCCTATGCCAGCAGTCTCT  
PAI-1 (Serpine 1) S CAGAGGGCCCCTGGAGAAGT 
PAI-1 (Serpine 1) A ATTGTCTCTGTCGGGTTGTGCC 
Pck1 (Pepck) S CCAACGTGGCCGAGACTAGCG 
Pck1 (Pepck) A GGCACATGGTTCCGCGTCCT 
PPARα S ATGCCAGTACTGCCGTTTTC 
PPARα A GGCCTTGACCTTGTTCATGT 
PPARβ/δ S TGGAGCTCGATGACATGTAC 
PPARβ/δ A GTACTGGCTGTCAGGGTGGT 
PPARγ S TCCGAAGAACCATCCGATTGAA 
PPARγ A CATACAAATGCTTTGCCAGGGC 
Rarres2 (chemerin) S ACCTGTGCAGTTGGCCTTCC 
Rarres2 (chemerin) A GAGGATCCTGAGGCCCTTGCT 
Retn (resistin) S CAGCATGCCACTGTGTCCCA 
Retn (resistin) A CACGAATGTCCCACGAGCCA 
TGF-β S GGACCGCAACAACGCCATCT 
TGF-β A CCTTGGTTCAGCCACTGCCG 
TNF-α S CCCTCACACTCAGATCATCTTCT 
TNF-α A GCTACGACGTGGGCTACAG 
Ucp1 (Uncoupling protein 1) S TCAGCTGTTCAAAGCACACA 
Ucp1 (Uncoupling protein 1) A GTACCAAGCTGTGCGATGTC 	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6	  Discussion	  
6.1 Brief summary of the results 
The data obtained in this PhD thesis shed light into the role of SIRT1 in atherosclerosis. In 
contrast to a published observation, endogenous SIRT1 seems to suppress inflammatory 
events rather than affecting vascular function in atherosclerotic ApoE-/- mice. In this regard, 
suppression of the NF-κB signaling pathway by SIRT1 is of crucial importance. The studies 
with ApoE-/- PGC-1α +/+ and ApoE-/- PGC-1α -/- mice did not clarify the exact role of PGC-1α 
in atherosclerosis, but propose that a balance between pro- and anti-atherogenic events 
governs the atherosclerotic phenotype of ApoE-/- PGC-1α -/- mice. 
6.2 Discussion of the individual projects 
SIRT1 in atherosclerosis 
Figure 8 summarizes the main findings regarding the role of SIRT1 in atherosclerosis. These 
findings are summarized based on the results obtained from experiments done with ApoE-/- 
SIRT1+/+ and ApoE-/- SIRT1+/- mice in vivo, with primary cells obtained from these mice ex 
vivo, with wild-type (WT) C57BL/6 mice treated with a SIRT1 inhibitor in vivo, and with 
genetic and pharmacological modulation of SIRT1 expression or activity in primary and/or 
established cancer lines from murine or human origin. 
SIRT1 in vascular function 
Some reports proposed that SIRT1 influences endothelium-dependent vascular function. 
SIRT1 deacetylates and activates eNOS in vitro and improves vascular function in aortic rings 
ex vivo (Mattagajasingh et al., 2007). During the course of this PhD thesis it has been further 
shown that endothelial overexpression of SIRT1 (SIRT1-Tg) prevents atherosclerosis by 
improving vascular function in atherosclerosis-prone ApoE-/- mice kept on a high-fat diet 
(Zhang et al., 2008a). This was very surprising since I have been doing similar organ chamber 
experiments using aortic rings of ApoE-/- SIRT1+/+ and ApoE-/- SIRT1+/- mice, and in contrast 
to Zhang et al., I did not observe any difference in endothelium-dependent vascular function 
(Stein et al., 2010c). Several reasons may explain this discrepancy: (1) In Zhang’s study not 
only did the WT and SIRT1-Tg mice fed a high-fat diet display endothelial dysfunction, but 
also the control WT and SIRT1-Tg mice fed a normal chow. Thus, the methodology and 
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reproducibility of the results by Zhang et al. is  not convincing. (2) Zhang et al. overexpressed 
the human SIRT1 gene in mouse endothelial cells. Even though SIRT1 is conserved from 
bacteria to humans, the possibility that the mouse and human enzymes may differently affect 
eNOS activity cannot be excluded. (3) ApoE-/- SIRT1+/- mice are haploinsufficient, meaning 
that the intact allele cannot compensate the lack of transcript from the deficient allele. If 
SIRT1 is essential for proper endothelium-dependent vascular function, haploinsufficient 
ApoE-/- SIRT1+/- mice should display a dysfunction. Nevertheless, we cannot exclude the 
possibility that the single allele produces sufficient protein to regulate eNOS. (4) Furthermore, 
the diets and treatment periods differ between the two studies. This discrepancy was also 
point of discussion in a commentary from Zhihong Yang and Xiu‐Fen Ming on our study 
(Yang and Ming, 2010). 
 
Figure 8 Role of SIRT1 in atherosclerosis 
SIRT1-mediated suppression of NF-κB signaling hinders the development of atherosclerosis 
at different stages (from left to right): In early stages it reduces the endothelial expression of 
adhesion molecules that attract monocytes and T cells to atheromatous lesions. In advanced 
stages SIRT1 suppresses the expression of Lox-1 and reduces uptake of oxLDL, thereby 
preventing macrophage foam cell formation. In the latest stage, during plaque rupture, 
SIRT1 may prevent atherothrombosis by downregulating the endothelial expression of 
tissue factor. 
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SIRT1 in endothelial activation 
The role of SIRT1 in endothelial activation is less controversial. Studies form our lab as well 
as others suggest that SIRT1 exerts anti-inflammatory effects in vascular endothelial cells 
(Csiszar et al., 2009; Csiszar et al., 2008; Gracia-Sancho et al., 2010). Our in vitro data 
showed that SIRT1 deacetylates RelA/p65 at K310 and suppresses its binding to naked DNA, 
therefore interfering with a crucial step in NF-κB signaling activation and reducing the 
expression of endothelial adhesion molecules (Stein et al., 2010c). These findings are in line 
with previous reports showing that SIRT1 deacetylates RelA/p65 at the lysine residue K310 in 
human epithelial lung cells (Yeung et al., 2004). In agreement with these reports, we 
demonstrated that this mechanism of RelA/p65 signaling suppression is present in HAECs. 
More importantly, we provided evidence that suppression of NF-κB signaling by SIRT1 also 
plays a role in vivo: Upon injection of lipopolysaccharide (LPS) to boost NF-κB signaling, 
endothelial expression of ICAM-1 and VCAM-1 was increased in non-atherosclerotic aortae 
of ApoE-/- SIRT1+/- compared to ApoE-/- SIRT1+/+ mice (Stein et al., 2010c). 
SIRT1 in macrophage function and foam cell formation 
In macrophages we demonstrated that SIRT1 suppresses the expression of Lox-1, reduces the 
uptake of oxLDL, and prevents macrophage foam cell formation (Stein et al., 2010b). While 
we focused our attention on oxLDL uptake and macrophage foam cell formation, other groups 
studied the roles of macrophage SIRT1 in inflammation, where SIRT1 prevents fatty acid-
induced inflammation (Yang et al., 2010), reduces the expression of many pro-inflammatory 
molecules such as TNF-α, MCP-1 and interleukins (Schug et al., 2010; Shen et al., 2009), 
modulates insulin sensitivity (Yoshizaki et al., 2010), and diminishes Cyclooxygenase 2 
(COX-2) expression and Prostaglandin E2 (PGE2) secretion (Zhang et al., 2010). The study 
from Schug et al. (2010), which appeared shortly after the publication of our respective 
results, is of special interest because they showed that SIRT1-deficient macrophages display 
NF-κB hyperacetylation that results in enhanced expression of various pro-inflammatory 
genes as well as increased accumulation of activated macrophages in the liver and adipose 
tissue in mice fed a high-fat diet (Schug et al., 2010). Other interesting studies show that 
macrophage SIRT1 regulates the expression of matrix metalloproteinases (MMP) and the 
MMP-regulator Tissue Inhibitor of MMP3 (TIMP3) under pathological conditions (Cardellini 
et al., 2009; Nakamaru et al., 2009). These findings suggest that SIRT1 does not only regulate 
the expression of scavenger receptors and cholesterol metabolism, but also has beneficial anti-
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inflammatory effects in macrophages and regulates the expression of MMPs, which promote 
plaque vulnerability. 
Our bone marrow (BM) transplantation (BMT) experiments confirmed that macrophage 
SIRT1 is crucial to prevent atherosclerosis (Stein et al., 2010b). However, an important 
control is missing in our study: The reverse experiment in which BM-derived cells from 
ApoE-/- mice would be transferred into irradiated ApoE-/- SIRT1+/+ and ApoE-/- SIRT1+/- mice. 
The reason why we did not perform the reverse experiment is that the ApoE-/- SIRT1+/- 
genotype was on a mixed genetic background whereas the ApoE-/- donors would have been on 
a pure C57BL/6 background. We confirmed that the transfer of 129/B6 BM into B6 recipients 
is well tolerated without graft-versus-host (GvH) disease. In contrast, the reverse transfer of 
pure B6 BM into 129/B6 recipients could potentially lead to adverse GvH reactions: Mature T 
cells present in the BM would be alloreactive towards the 129-MHC. After having 
backcrossed the ApoE-/- SIRT1+/- mice with mixed genetic background to pure C57BL/6 
background, this reverse BMT experiment could be performed without any limitation. 
SIRT1 in reverse cholesterol transport 
So far only one study shows that SIRT1 regulates cholesterol efflux: Li et al. demonstrated 
that SIRT1 directly deacetylates and thereby regulates the transcriptional activity of LXRα, an 
important regulator of lipid homeostasis and inflammation (Li et al., 2007). Activation of 
LXRα leads to expression of the ATP-binding cassette (ABC) transporter A1 (ABCA1) that 
regulates the efflux of cholesterol into pre-βHDL particles. Indeed, Li et al. show that 
cholesterol efflux from primary SIRT1+/+ is higher than from SIRT1-/- macrophages. 
Furthermore, the authors claim that the SIRT1 inhibitor NAM inhibits cholesterol efflux in 
the human monocytic cell line THP-1 (Li et al., 2007). In contrast, we did not observe any 
change in cholesterol efflux in the mouse macrophage cell line RAW 246.7 upon treatment 
with the SIRT1 inhibitor splitomicin (Stein et al., 2010b). The different inhibitors or cell types 
that have been used may explain the controversial results. Neither NAM nor splitomicin are 
solely specific for SIRT1. NAM is an end product inhibitor of the deacetylation reaction 
mediated by the NAD+-dependent sirtuins (Bitterman et al., 2002), and therefore an inhibitor 
of all NAD+-dependent enzymes. Splitomicin was identified as an inhibitor of the 
Saccharomyces cerevisiae Sir2p (Bedalov et al., 2001). Although splitomicin shows weak 
inhibitory potential towards human SIRT1 (Hirao et al., 2003; Posakony et al., 2004), it has 
been successfully used by different groups to inhibit human or mouse SIRT1 (Biacsi et al., 
2008; Hou et al., 2008; Kim et al., 2007a; Prozorovski et al., 2008). Future studies using 
 
- 101 -
 
 
different specific SIRT1 inhibitors and activators as well as genetic approaches are necessary 
to confirm a role of SIRT1 in cholesterol efflux regulation in vivo. 
SIRT1 in atherothrombosis 
In the latest stage of atherogenesis, during plaque rupture, SIRT1 may prevent 
atherothrombosis by downregulating the endothelial expression of tissue factor. Indeed, 
treatment of wild-type mice with the SIRT1 inhibitor splitomicin in vivo enhanced tissue 
factor activity and markedly reduced the time upon coagulation in a photochemical vascular 
injury model (occlusion was defined as a flow of ≤0.1 ml/min for at least 1 minute) 
(Breitenstein et al., 2010). In vitro, we could show that SIRT1 diminishes tissue factor 
expression by deacetylating RelA/p65 and suppressing NF-κB signaling in HAECs. Inhibition 
or siRNA-mediated SIRT1 silencing in HAECs stimulated with inflammatory mediators lead 
to increased tissue factor expression (Breitenstein et al., 2010). Patients with atherosclerosis 
have elevated levels of tissue factor (Reilly et al., 2007) and even higher concentrations are 
measured in the area around the culprit lesion in patients with unstable angina or acute 
myocardial infarction compared to patients with stable angina (Annex et al., 1995; Ardissino 
et al., 1997). Our studies showing that SIRT1 reduces atherosclerosis and arterial thrombosis 
suggest SIRT1 activation as a promising therapeutic strategy in these patients. 
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PGC-1α in atherosclerosis 
In order to test the role of PGC-1a in atherosclerosis, a genetic approach was used: We 
observed no difference in atherosclerosis between ApoE-/- PGC-1α-/- and ApoE-/- PGC-1α+/+ 
mice. However, ApoE-/- PGC-1α-/- mice were leaner, had lighter liver and epididymal WAT, 
and less cholesterol and triglycerides in VLDL and LDL subfractions than ApoE-/- PGC-1α+/+ 
mice (Stein et al., 2010a). This phenotype is in line with the first study that described the 
phenotype of PGC-1α-/- mice, which also have markedly reduced body fat content (Lin et al., 
2004a). Thus, the effects of PGC-1a on atherosclerosis may be attributed to these confounding 
factors, under which a clear cause-effect relationship could not be established. 
Several of our findings suggest that less atherosclerosis should be exprected in ApoE-/- PGC-
1α-/- compared to ApoE-/- PGC-1α+/+ mice: (1) reduced body and fat weight (Stevens et al., 
1998), (2) less visceral WAT inflammation (Ohman et al., 2008), (3) diminished aortic and 
plasma levels of IL-18 (Elhage et al., 2003; Mallat et al., 2001; Tenger et al., 2005; Whitman 
et al., 2002), and (4) lower cholesterol and TG content in VLDL and IDL/LDL particles 
(Drexel et al., 1994; Goldstein et al., 1983). Since we do not observe any difference in 
atherosclerosis between ApoE-/- PGC-1α-/- and ApoE-/- PGC-1α+/+ mice (Stein et al., 2010a), 
there have to be pro-atherogenic contributions that resemble the anti-atherogenic functions of 
PGC-1α that are lacking in these mice (Figure 9). 
 
Figure 9 Atherosclerotic balance model of ApoE-/- PGC-1α-/- mice 
ApoE-/- PGC-1α-/- mice do not develop more atherosclerosis than ApoE-/- PGC-1α+/+ mice. 
Our data suggests that the contribution of pro and anti-atherogenic functions mediated by 
PGC-1α is balanced. For example, a pro-atherogenic contribution is the enhanced adipsin 
expression in WAT, and an anti-atherogenic contribution the reduced expression of IL-18 in 
WAT and aortae. 
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Our data proposes two possible pro-atherogenic contributions in ApoE-/- PGC-1α-/- mice. 
First, the reduced aortic expression of PPARα and PPARγ as well as of PPAR target genes 
proposes that the function of these two PPARs is suppressed in ApoE-/- PGC-1α-/- mice (Stein 
et al., 2010a). Importantly, both PPARα and PPARγ can exert anti-atherogenic functions in 
the arterial wall. For example, administration of the PPARγ ligand rosiglitazone reduces foam 
cell formation and atherosclerosis in LDL-R knockout mice (Li et al., 2000), and 
transplantation of PPARγ-deficient bone marrow into recipient LDL-R knockout mice 
enhanced atherosclerosis (Chawla et al., 2001).  
The second pro-atherogenic contribution is the increased expression of adipsin in WAT (Stein 
et al., 2010a). Adipsin is a serine protease that cleaves factor B in the alternative complement 
pathway, and it is secreted at high levels in adipose tissue (Cook et al., 1987; Min and 
Spiegelman, 1986; White et al., 1992). Notably, expression of adipsin and other components 
of the alternative complement pathway correlate with atherosclerosis (Recinos et al., 2004). 
The main limitation of our study is the complex phenotype of the ApoE-/- PGC-1α-/- mice. The 
interplay of direct or indirect endocrine, paracrine and autocrine PGC-1α-driven effects is to 
complex to distinguish between the single specific effects that PGC-1α may exert in different 
tissues. Therefore, future studies using tissue-specific PGC-1α knock-in or knock-out mice 
will be necessary to study these effects. 
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6.3 Perspectives 
SIRT1 - a potent anti-inflammatory molecule 
Many studies, including our own, demonstrate that SIRT1 exhibits anti-inflammatory 
properties both in vitro (e.g. fatty acid-induced inflammation), and in vivo (e.g. myeloid 
deletion, atherosclerosis, sustainment of normal immune function in knock-out mice) as well 
as in clinical studies (e.g. COPD patients) (Breitenstein et al., 2010; Rajendrasozhan et al., 
2008; Schug et al., 2010; Sequeira et al., 2008; Stein et al., 2010b; Stein et al., 2010c; Yang et 
al., 2010). These studies propose that SIRT1 activation may be a promising strategy for 
treating chronic inflammatory diseases, such as atherosclerosis and atherothrombosis (Figure 
10). 
 
Figure 10 SIRT1 as therapeutic target for patients with atherosclerosis  
Pharmacological activation of SIRT1 diminishes atherogenesis by suppressing NF-kB 
signaling-mediated pro-inflammatory events. Therefore SIRT1 may be a promising 
therapeutical target for patients with atherosclerosis or atherothrombosis. 
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Indeed, several SIRT1 activators have been developed by Sirtris™ Pharmaceuticals (Milne et 
al., 2007). While some studies claim that these Sirtris™ activators are specific (Dai et al., 
2010; Funk et al., 2010; Yamazaki et al., 2009), others demonstrated that these compounds do 
not act via direct SIRT1 activation (Pacholec et al., 2010). According to Sirtris™ 
Pharmaceuticals new SIRT1-activating drugs are being developed and tested in phase IIa 
clinical trials in patients with type 2 diabetes, inflammation and cardiovascular disease 
(www.sirtrispharma.com). Future studies will be necessary to better understand the SIRT1 
specificity, clinical effects and side effects of these promising activators. 
Preventing NF-κB signaling pathway activation to treat atherosclerosis 
The NF-κB pathway plays an important role in atherosclerosis. Numerous studies show a link 
between NF-κB pathway activation and disease development and/or progression. Of note, 
different stimuli/regulators, different cell types and time points have different anti- or pro-
atherogenic effects (Collins and Cybulsky, 2001; Kutuk and Basaga, 2003; Xanthoulea et al., 
2005), suggesting that the particular tissue milieu determines the final outcome related to NF-
κB pathway activation. 
Several studies suggest a direct correlation between the activation of the NF-κB signaling 
pathway and atherosclerosis. The pro-inflammatory NF-κB-dependent response in human 
atherosclerotic lesions is mediated by the canonical NF-κB pathway, including the p65, p50 
and c-Rel subunits of NF-κB as well as the IKK2 kinase (Monaco et al., 2004). Endothelial 
cell-specific disruption of the NF-κB pathway prevents the expression of pro-inflammatory 
adhesion molecules and protects ApoE-/- mice from atherosclerosis (Gareus et al., 2008). 
Furthermore, several pharmacological agents, including statins, angiotensin-converting 
enzyme (ACE) inhibitors or the phytohormone genistein, prevent atherosclerosis at least in 
part by suppressing the NF-κB pathway (Choi et al., 2003; Hernandez-Presa et al., 1997; 
Hernandez-Presa et al., 1998; Lopez-Franco et al., 2006; Wang et al., 2008; Yang et al., 
2006). Finally, clinical studies propose that the activation of the NF-κB signaling pathway is 
enhanced in patients with advanced atherosclerosis (Martin-Ventura et al., 2004; Zhang et al., 
2009).  
On the other hand, the function of macrophage NF-κB signaling in foam cell formation and 
atherosclerosis remains controversial. Macrophage-restricted deletion of IκB kinase (IKK2) to 
disrupt NF-κB signaling increases atherosclerosis in LDL-R knockout mice (Kanters et al., 
2003). Conversely, studies using macrophage-specific p50 deletion or a dominant-negative 
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IκBα mutant to disrupt NF-κB signaling resulted in diminished uptake of lipoproteins and less 
atherosclerosis (Ferreira et al., 2007; Kanters et al., 2004). NF-κB terminates its own 
activation by inducing the expression of IκBα and A20. While haploinsufficient ApoE-/- 
A20+/- mice develop more atherosclerosis than control ApoE-/- A20+/+ mice, overexpression 
of A20 decreases atherosclerosis, suggesting that A20 diminishes atherosclerosis by 
decreasing NF-κB activity (Wolfrum et al., 2007). 
It may therefore be more promising to modulate the function of regulators (Ahn et al., 2007). 
For example, inhibition of HATs that acetylate RelA/p65 or activation of HDACs that 
deacetylate RelA/p65 may block NF-κB pathway activation and, therefore exert anti-
atherogenic properties. 
To test whether acetylation/deacetylation of RelA/p65 affects atherosclerosis in vivo, it would 
be interesting to compare mice with a mutation affecting acetylatable lysines of RelA/p65, 
such as K310R as non-acetylatable and K310Q as acetylation mimic mutants. For example, 
crossing K310R-RelA/p65 mice into an ApoE-/- SIRT1+/- background would demonstrate 
which of the observed effects of this thesis are really mediated by SIRT1-dependent acK310-
RelA/p65 deacetylation. 
Understanding the effect of posttranscriptional modifications of components of the NF-κB 
signaling pathway on the transcriptional regulation of its target genes is crucial for future 
pharmacological approaches. Therefore, further investigations will be needed to precisely 
understand the effect of these modifications and to translate these approaches to the clinical 
arena. 
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